Comprehensive Addiction Resources Emergency Act of 2019

H.R. 2466: State Opioid Response Grant Authorization Act H.R. 2922: Respond Now Act H.R. 3496, S. 1983: Create Opportunities Act H.R. 2569, S. 1365: Comprehensive Addiction Resources Emergency Act H.R. 3797, Medical Marijuana Research Act S.2032, Cannabidiol and Marihuana Research Expansion Act Re-Authorize Residential Substance Abuse Treatment Act of 2020(Discussion draft, no bill number) S. 5000: CARA 2.0

Client expense: $216,000 · Firm income: Not reported

Government targets: Defense, Dept of (DOD), Education, Dept of, HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Institutes of Health (NIH), Natl Science Foundation (NSF), SENATE

Drug overdose prevention, expanding access to drug treatment and harm reduction services. HR 2482/S 2074, the Medication Assisted Treatment Act; HR 2569/S 1365, Comprehensive Addiction Resources Emergency Act.

Client expense: $87,644 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Teaching Health Centers; 340B Drug Discount Program; Title X Program, Training the Next Generation of Primary Care Doctors (S.304/H.R.2815); Funding for School-Based Health Centers(S.1365/H.R.2569); Lower Drug Costs Now Act of 2019 (H.R.3); Prescription Drug Pricing Reduction Act of 2019 (S. 2543); COVID-19 response legislation, including the Coronavirus Aid, Relief, and Economic Security Act (CARES ACT), Families First Coronavirus Response Act, and Coronavirus Preparedness and Response Supplemental Appropriations Act, 2020; Strengthening Americas Health Care Readiness Act (S.4055).

Client expense: $200,000 · Firm income: Not reported

Government targets: Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, Health Resources & Services Administration (HRSA), Office of Management & Budget (OMB), SENATE, White House Office

Maternal and child health legislation,focusing on National Children's Study (ECHO), Zika preparedness, tobacco control, opioids legislation and neonatal abstinence syndrome (NAS), antibiotic resistance, environmental health, vaccination, newborn screening, Healthy Start, maternal mental health. Specific legislation includes: MOMMAs Act (H.R. 1897/S. 916, MOMs Act (S. 116),MOMMIES Act (H.R. 2602, S. 1343), Quality Care for Moms and Babies Act (H.R. 1551/S. 1960), Maternal CARE Act (H.R. 6698/S. 1600), The Healthy Maternity and Obstetric Medicine Act (Healthy MOM Act) (H.R. 2778/S. 1481), Rural Maternal and Obstetric Modernization of Services (MOMS) Act (S. 2373), the Maternal Outcomes Matter Act of 2019 (S. 2586), Healthy Maternity and Obstetric Medicine Act (H.R. 2778, S. 1481), H.R. 4995, Maternal Health Quality Improvement Act of 2019, H.R. 4996, Helping Medicaid Offer Maternity Services Act of 2019, Reversing the Youth Tobacco Epidemic Act (H.R. 2339), Public Health Funding Restoration Act (H.R. 3447, S. 1944), and the Comprehensive Addiction Resources Emergency CARE Act (H.R. 2569, S. 1365), Newborn Screening Saves Lives Reauthorization Act of 2019 (HR 2507/S. 2158), Traveling Parents Screening Consistency Act (HR 3246), the Tobacco Tax Equity Act (S. 2517), EQUIP Act of 2020 (HR 6178), and the Protecting American Lungs Act of 2019 (HR 4742). Black Maternal Health Momnibus Act of 2020 (HR 6142)including the Social Determinants for Moms Act (HR 6132), the Protecting Moms who Served Act (HR 6164), the Data to Save Moms Act (HR 6165), the Moms MATTER Act (HR 6143), and Kira Johnson Act (HR 6144). Coronavirus Preparedness and Response Supplemental Appropriations Act, 2020 (P.L. 116-123), Families First Coronavirus Response Act (P.L. 116-127), Coronavirus Aid, Relief, and Economic Security (CARES) Act (HR 748) (P.L. 116-136), and HEROES Act (H.R. 6800). Mothers and Newborns Success Act (S.4269), Maternal Health Pandemic Response Act of 2020 (H.R. 8027), Community Immunity During COVID-19 Act of 2020 (H.R. 8061), Maternal Immunization Enhancement Act (S.4690), Public Health Infrastructure Saves Lives Act (PHISLA), COVID-19 Treatment Coverage Act (S.4469)

Client expense: $50,000 · Firm income: Not reported

Government targets: Agriculture, Dept of (USDA), Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Environmental Protection Agency (EPA), Federal Reserve System, Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), Internal Revenue Service (IRS), Labor, Dept of (DOL), Natl Institutes of Health (NIH), Postal Regulatory Commission, SENATE, Treasury, Dept of, U.S. Postal Service (USPS)

H.R. 3591: Campus Prevention and Recovery Services for Students Act of 2019 H.R. 2466: State Opioid Response Grant Authorization Act H.R. 2922: Respond Now Act H.R. 3489, S. 1204: Higher Education Mental Health Act of 2019 H.R. 3496, S. 1983: Create Opportunities Act H.R. 2569, S. 1365: Comprehensive Addiction Resources Emergency Act

Client expense: $280,000 · Firm income: Not reported

Government targets: Agriculture, Dept of (USDA), Commerce, Dept of (DOC), Defense, Dept of (DOD), Education, Dept of, HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Justice, Dept of (DOJ), Labor, Dept of (DOL), Natl Science Foundation (NSF), Natl Security Agency (NSA), SENATE, Veterans Affairs, Dept of (VA)

Drug overdose prevention, expanding access to drug treatment and harm reduction services. HR 2482/S 2074, the Medication Assisted Treatment Act; HR 2569/S 1365, Comprehensive Addiction Resources Emergency Act.

Client expense: $87,644 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Price transparency, out-of-network reimbursement of emergency medical services, surprise medical bills Opioids, pain management Federal funding for Substance Use Disorder treatments Drug Shortages P.L.116-139-Paycheck Protection Program and Health Care Enhancement Act P.L.116-142-Paycheck Protection Program Flexibility Act of 2020 H.R.501-Poison Center Network Enhancement Act of 2019 H.R.861-End Surprise Billing Act of 2019 H.R.1301-Mental Health Telemedicine Expansion Act H.R.1309-Workplace Violence Prevention for Health Care and Social Service Workers Act H.R.1418-Competitive Health Insurance Reform Act of 2019 H.R.1554-Resident Education Deferred Interest (REDI) Act H.R.1682-Improving Access to Medicare Coverage Act of 2019 H.R.1767-Excellence in Mental Health and Addiction Treatment Expansion Act H.R.2281-Easy Medication Access and Treatment (MAT) for Opioid Addiction Act H.R.2328-Reauthorizing and Extending Americas Community Health Act H.R.2464-End the Cycle of Violence Act of 2019 H.R.2482-Mainstreaming Addiction Treatment Act of 2019 H.R.2519-Improving Mental Health Access from the Emergency Department Act of 2019 H.R.2550-Prevent Blood Loss with Emergency Equipment Devices Act of 2019 H.R.2569-Comprehensive Addiction Resources Emergency Act of 2019 H.R.3107-Improving Seniors Timely Access to Care Act of 2019 H.R.3417-Beneficiary Education Tools, Telehealth, and Extenders Reauthorization Act of 2019 H.R.3502-Protecting People From Surprise Medical Bills Act H.R.3630-No Surprises Act H.R.3984-Health Care Safety Net Enhancement Act of 2019 H.R.4861-Effective Suicide Screening and Assessment in the Emergency Department Act of 2019 H.R.4932-Creating Opportunities Now for Necessary and Effective Care Technologies for Health Act of 2019 H.R.5800-Ban Surprise Billing Act H.R.5826-Consumer Protections Against Surprise Medical Bills Act of 2020 H.R.6800-Health and Economic Recovery Omnibus Emergency Solutions (HEROES) Act H.R.6910-Emergency Room Hero and Patient Safety Act H.R.7059-Coronavirus Provider Protection Act H.R.7255-Coronavirus Health Care Worker Wellness Act of 2020 S.289-Rural Physician Workforce Production Act of 2019 S.299-Geriatrics Workforce Improvement Act S.350-Competitive Health Insurance Reform Act of 2019 S.618-Medicare Choices Empowerment and Protection Act S.753-Improving Access to Medicare Coverage Act of 2019 S.824-Excellence in Mental Health and Addiction Treatment Expansion Act S.851-Workplace Violence Prevention for Health Care and Social Service Workers Act S.1199-Poison Center Network Enhancement Act of 2019 S.1266-Protecting Patients from Surprise Medical Bills Act S.1334-Improving Mental Health Access from the Emergency Department S.1350-Good Samaritan Health Professionals Act of 2019 S.1365-Comprehensive Addiction Resources Emergency Act of 2019 S.1531-Stopping The Outrageous Practice of Surprise Medical Bills Act of 2019 S.1895-Lower Health Care Costs Act S.2074-Mainstreaming Addiction Treatment Act of 2019 S.2741-Creating Opportunities Now for Necessary and Effective Care Technologies (CONNECT) for Health Act of 2019 S.3006-Effective Suicide Screening and Assessment in the Emergency Department Act of 2019 S.3143-Magnet Injury Prevention Act S.3346-Prevent Blood Loss with Emergency Equipment Devices Act of 2020

Client expense: $314,376 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Opioids, pain management Federal funding for Substance Use Disorder treatments H.R.2281-Easy Medication Access and Treatment (MAT) for Opioid Addiction Act H.R.2482-Mainstreaming Addiction Treatment Act of 2019 H.R.2569-Comprehensive Addiction Resources Emergency Act of 2019 S.1365-Comprehensive Addiction Resources Emergency Act of 2019 S.2074-Mainstreaming Addiction Treatment Act of 2019

Client expense: $314,376 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Opioids, pain management Federal funding for Substance Use Disorder treatments H.R.2281-Easy Medication Access and Treatment (MAT) for Opioid Addiction Act H.R.2482-Mainstreaming Addiction Treatment Act of 2019 H.R.2569-Comprehensive Addiction Resources Emergency Act of 2019 S.1365-Comprehensive Addiction Resources Emergency Act of 2019 S.2074-Mainstreaming Addiction Treatment Act of 2019

Client expense: $595,871 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Price transparency, out-of-network reimbursement of emergency medical services, surprise medical bills Opioids, pain management Federal funding for Substance Use Disorder treatments Drug Shortages H.R.501-Poison Center Network Enhancement Act of 2019 H.R.861-End Surprise Billing Act of 2019 H.R.1301-Mental Health Telemedicine Expansion Act H.R.1309-Workplace Violence Prevention for Health Care and Social Service Workers Act H.R.1418-Competitive Health Insurance Reform Act of 2019 H.R.1554-Resident Education Deferred Interest (REDI) Act H.R.1682-Improving Access to Medicare Coverage Act of 2019 H.R.1767-Excellence in Mental Health and Addiction Treatment Expansion Act H.R.2281-Easy Medication Access and Treatment (MAT) for Opioid Addiction Act H.R.2328-Reauthorizing and Extending Americas Community Health Act H.R.2464-End the Cycle of Violence Act of 2019 H.R.2482-Mainstreaming Addiction Treatment Act of 2019 H.R.2519-Improving Mental Health Access from the Emergency Department Act of 2019 H.R.2550-Prevent Blood Loss with Emergency Equipment Devices Act of 2019 H.R.2569-Comprehensive Addiction Resources Emergency Act of 2019 H.R.3107-Improving Seniors Timely Access to Care Act of 2019 H.R.3417-Beneficiary Education Tools, Telehealth, and Extenders Reauthorization Act of 2019 H.R.3502-Protecting People From Surprise Medical Bills Act H.R.3630-No Surprises Act H.R.3984-Health Care Safety Net Enhancement Act of 2019 H.R.4861-Effective Suicide Screening and Assessment in the Emergency Department Act of 2019 H.R.4932-Creating Opportunities Now for Necessary and Effective Care Technologies for Health Act of 2019 H.R.5800-Ban Surprise Billing Act H.R.5826-Consumer Protections Against Surprise Medical Bills Act of 2020 S.289-Rural Physician Workforce Production Act of 2019 S.299-Geriatrics Workforce Improvement Act S.350-Competitive Health Insurance Reform Act of 2019 S.618-Medicare Choices Empowerment and Protection Act S.753-Improving Access to Medicare Coverage Act of 2019 S.824-Excellence in Mental Health and Addiction Treatment Expansion Act S.851-Workplace Violence Prevention for Health Care and Social Service Workers Act S.1199-Poison Center Network Enhancement Act of 2019 S.1266-Protecting Patients from Surprise Medical Bills Act S.1334-Improving Mental Health Access from the Emergency Department S.1350-Good Samaritan Health Professionals Act of 2019 S.1365-Comprehensive Addiction Resources Emergency Act of 2019 S.1531-Stopping The Outrageous Practice of Surprise Medical Bills Act of 2019 S.1895-Lower Health Care Costs Act S.2074-Mainstreaming Addiction Treatment Act of 2019 S.2741-Creating Opportunities Now for Necessary and Effective Care Technologies (CONNECT) for Health Act of 2019 S.3006-Effective Suicide Screening and Assessment in the Emergency Department Act of 2019 S.3143-Magnet Injury Prevention Act S.3346-Prevent Blood Loss with Emergency Equipment Devices Act of 2020

Client expense: $595,871 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Maternal and child health legislation,focusing on National Children's Study (ECHO), Zika preparedness, tobacco control, opioids legislation and neonatal abstinence syndrome (NAS), antibiotic resistance, environmental health, vaccination, newborn screening, Healthy Start, maternal mental health. Specific legislation includes: MOMMAs Act (H.R. 1897/S. 916, MOMs Act (S. 116),MOMMIES Act (H.R. 2602, S. 1343), Quality Care for Moms and Babies Act (H.R. 1551/S. 1960), Maternal CARE Act (H.R. 6698/S. 1600), The Healthy Maternity and Obstetric Medicine Act (Healthy MOM Act) (H.R. 2778/S. 1481), Rural Maternal and Obstetric Modernization of Services (MOMS) Act (S. 2373), the Maternal Outcomes Matter Act of 2019 (S. 2586), Healthy Maternity and Obstetric Medicine Act (H.R. 2778, S. 1481), H.R. 4995, Maternal Health Quality Improvement Act of 2019, H.R. 4996, Helping Medicaid Offer Maternity Services Act of 2019, Reversing the Youth Tobacco Epidemic Act (H.R. 2339), Public Health Funding Restoration Act (H.R. 3447, S. 1944), and the Comprehensive Addiction Resources Emergency CARE Act (H.R. 2569, S. 1365), Newborn Screening Saves Lives Reauthorization Act of 2019 (HR 2507/S. 2158), Traveling Parents Screening Consistency Act (HR 3246), the Tobacco Tax Equity Act (S. 2517), EQUIP Act of 2020 (HR 6178), and the Protecting American Lungs Act of 2019 (HR 4742). Black Maternal Health Momnibus Act of 2020 (HR 6142)including the Social Determinants for Moms Act (HR 6132), the Protecting Moms who Served Act (HR 6164), the Data to Save Moms Act (HR 6165), the Moms MATTER Act (HR 6143), and Kira Johnson Act (HR 6144). Coronavirus Preparedness and Response Supplemental Appropriations Act, 2020 (P.L. 116-123), Families First Coronavirus Response Act (P.L. 116-127), Coronavirus Aid, Relief, and Economic Security (CARES) Act (HR 748) (P.L. 116-136), and HEROES Act (H.R. 6800).

Client expense: $50,000 · Firm income: Not reported

Government targets: Agriculture, Dept of (USDA), Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Environmental Protection Agency (EPA), Federal Reserve System, Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), Internal Revenue Service (IRS), Labor, Dept of (DOL), Natl Institutes of Health (NIH), Postal Regulatory Commission, SENATE, Treasury, Dept of, U.S. Postal Service (USPS)

Teaching Health Centers; 340B Drug Discount Program; Title X Program, Training the Next Generation of Primary Care Doctors (S.304/H.R.2815); Funding for School-Based Health Centers(S.1365/H.R.2569); Lower Drug Costs Now Act of 2019 (H.R.3); Prescription Drug Pricing Reduction Act of 2019 (S. 2543); COVID-19 response legislation, including the Coronavirus Aid, Relief, and Economic Security Act (CARES ACT), Families First Coronavirus Response Act, and Coronavirus Preparedness and Response Supplemental Appropriations Act, 2020; Strengthening Americas Health Care Readiness Act (S.4055).

Client expense: $210,000 · Firm income: Not reported

Government targets: Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, Health Resources & Services Administration (HRSA), Office of Management & Budget (OMB), SENATE, White House Office

H.R. 3591: Campus Prevention and Recovery Services for Students Act of 2019 H.R. 2466: State Opioid Response Grant Authorization Act H.R. 2922: Respond Now Act H.R. 3489, S. 1204: Higher Education Mental Health Act of 2019 H.R. 3496, S. 1983: Create Opportunities Act H.R. 2569, S. 1365: Comprehensive Addiction Resources Emergency Act

Client expense: $320,000 · Firm income: Not reported

Government targets: Agency for Healthcare Research & Quality (AHRQ), Agriculture, Dept of (USDA), Commerce, Dept of (DOC), Defense, Dept of (DOD), Education, Dept of, Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Justice, Dept of (DOJ), Labor, Dept of (DOL), Natl Institutes of Health (NIH), Natl Science Foundation (NSF), Natl Security Agency (NSA), Office of Natl Drug Control Policy (NDCP), SENATE, Veterans Affairs, Dept of (VA)

Drug overdose prevention, expanding access to drug treatment and harm reduction services. HR 2482/S 2074, the Medication Assisted Treatment Act; HR 2569/S 1365, Comprehensive Addiction Resources Emergency Act. Supported efforts to release vulnerable individuals from incarcerated settings.

Client expense: $87,644 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, SENATE

COVID-19 impact on mental health and addiction Relief for SUD treatment facilities and providers Telehealth Remote Recovery Support Medication Assisted Treatment SUD privacy standards (42 CFR Part 2) Public Health Workforce H.Res. 419, Resolution recognizing the contributions of the Addiction Profession workforce Improving Access to Remote Behavioral Health Treatment Act (S. 2244, H.R. 4131) Comprehensive Addiction Resources Emergency (CARE) Act (S. 1365, H.R. 2569) Parity Enforcement Act (H.R. 2848) Behavioral Health Coverage Transparency Act (H.R.2874, S.1576) Mental Health Parity Compliance Act (H.R.3165, S.1737) Medicaid Reentry Act (H.R. 1329) Addiction Treatment Access Act (S. 2412) Overdose Prevention and Patient Safety Act (H.R. 2062) USPS Opioid & Illicit Drug Strategy Act of 2019 (S.2974) SUD Loan Repayment Program: Section 7071 of the Substance Use-Disorder Prevention that Promotes Opioid Recovery and Treatment (SUPPORT) for Patients and Communities Act (P.L. 115-271) HEROES Act (H.R. 6800) Mental Health Research Act (H.R. 6645) Health Care Protection Act (H.R. 6810) Mental Health Services for Students Act (H.R. 1109/ S. 1122)

Client expense: Not reported · Firm income: $30,000

Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, White House Office

Maternal and child health legislation,focusing on National Children's Study (ECHO), Zika preparedness, tobacco control, opioids legislation and neonatal abstinence syndrome (NAS), antibiotic resistance, environmental health, vaccination, newborn screening, Healthy Start, maternal mental health. Specific legislation includes: MOMMAs Act (H.R. 1897/S. 916, MOMs Act (S. 116),MOMMIES Act (H.R. 2602, S. 1343), Quality Care for Moms and Babies Act (H.R. 1551/S. 1960), Maternal CARE Act (H.R. 6698/S. 1600), The Healthy Maternity and Obstetric Medicine Act (Healthy MOM Act) (H.R. 2778/S. 1481), Rural Maternal and Obstetric Modernization of Services (MOMS) Act (S. 2373), the Maternal Outcomes Matter Act of 2019 (S. 2586), Healthy Maternity and Obstetric Medicine Act (H.R. 2778, S. 1481), H.R. 4995, Maternal Health Quality Improvement Act of 2019, H.R. 4996, Helping Medicaid Offer Maternity Services Act of 2019, Reversing the Youth Tobacco Epidemic Act (H.R. 2339), Public Health Funding Restoration Act (H.R. 3447, S. 1944), and the Comprehensive Addiction Resources Emergency CARE Act (H.R. 2569, S. 1365), Newborn Screening Saves Lives Reauthorization Act of 2019 (HR 2507/S. 2158), Traveling Parents Screening Consistency Act (HR 3246), the Tobacco Tax Equity Act (S. 2517), EQUIP Act of 2020 (HR 6178), and the Protecting American Lungs Act of 2019 (HR 4742). Black Maternal Health Momnibus Act of 2020 (HR 6142)including the Social Determinants for Moms Act (HR 6132), the Protecting Moms who Served Act (HR 6164), the Data to Save Moms Act (HR 6165), the Moms MATTER Act (HR 6143), and Kira Johnson Act (HR 6144). Coronavirus Preparedness and Response Supplemental Appropriations Act, 2020 (P.L. 116-123), Families First Coronavirus Response Act (P.L. 116-127), and Coronavirus Aid, Relief, and Economic Security (CARES) Act (HR 748) (P.L. 116-136).

Client expense: $50,000 · Firm income: Not reported

Government targets: Agriculture, Dept of (USDA), Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Environmental Protection Agency (EPA), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), Internal Revenue Service (IRS), Labor, Dept of (DOL), Natl Institutes of Health (NIH), Postal Regulatory Commission, SENATE, Treasury, Dept of, U.S. Postal Service (USPS)

Teaching Health Centers; 340B Drug Discount Program; Title X Program, Training the Next Generation of Primary Care Doctors (S.304/H.R.2815); Funding for School-Based Health Centers(S.1365/H.R.2569); Lower Drug Costs Now Act of 2019 (H.R.3); Prescription Drug Pricing Reduction Act of 2019 (S. 2543); COVID-19 response legislation, including the Coronavirus Aid, Relief, and Economic Security Act (CARES ACT), Families First Coronavirus Response Act, and Coronavirus Preparedness and Response Supplemental Appropriations Act, 2020.

Client expense: $220,000 · Firm income: Not reported

Government targets: Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, Health Resources & Services Administration (HRSA), Office of Management & Budget (OMB), SENATE, White House Office

The Coronavirus Preparedness and Response Supplemental Appropriations Act, 2020 (H.R. 6074), all provisions related to relief funding, telehealth, and Medicare in response to the novel, COVID-19 pandemic. The Families First Coronavirus Response Act (H.R. 6201), all provisions related to relief funding, Medicaid, and paid leave in response to the novel, COVID-19 pandemic. The Coronavirus Aid, Relief, and Economic Security (CARES) Act (H.R. 748), all provisions related to relief funding in response to the novel, COVID-19 pandemic. The Special Registration for Telemedicine Clarification Act (H.R. 5483 (115)), all provisions related to establishing a special registration process with the Drug Enforcement Agency (DEA) for certain providers that wish to prescribe controlled substances via telemedicine. Mainstreaming Addiction Treatment Act (S. 2074/H.R. 2482), all provisions related to removing the waiver requirement for health care providers to prescribe buprenorphine for opioid use disorder. National Suicide Hotline Designation Act of 2019 (H.R. 4194), all provisions related to requiring the Federal Communications Commission designate 9-8-8 as a universal national suicide prevention and mental health crisis hotline number. Improving Access to Remote Behavioral Health Treatment Act of 2019 (S. 2244/H.R. 4131), all provisions related to amending regulations for the Ryan Haight Online Pharmacy Consumer Protection Act of 2008 and allowing community mental health centers to register to practice telemedicine. Comprehensive Addiction Resources Emergency Act of 2019 (S. 1365/H.R. 2569), all provisions related to providing emergency assistance to areas affected by the opioid epidemic, as well as grant funding for substance use disorder treatment research. Medication Access and Training Expansion Act of 2019 (H.R. 4974), all provisions related to prescriber training on treating patients with opioid and other substance use disorders. Resilience Investment, Support and Expansion from Trauma Act (S. 1770/H.R. 3180), all provisions related to supporting children and families who experience trauma. CREATE Opportunities Act (S. 1983/H.R. 3496), all provisions related to providing medication-assisted treatment to individuals with opioid use disorder and are incarcerated. Primary and Behavioral Health Care Access Act (H.R. 5575), all provisions related to requiring group health plans and health insurance issuers to provide for primary and behavioral health care visits without cost-sharing. Ensuring Patient Access to Critical Breakthrough Products Act of 2019 (H.R. 5333), all provisions related to ensuring prompt coverage of breakthrough devices under the Medicare program.

Client expense: $125,180 · Firm income: Not reported

Government targets: Drug Enforcement Administration (DEA), Federal Communications Commission (FCC), HOUSE OF REPRESENTATIVES, SENATE

H.R. 748 - Coronavirus Aid, Relief, and Economic Security (CARES) Act [P.L. No. 116-136] H.R. 6201, the Families First Coronavirus Response Act H.R. 6047, the Coronavirus Preparedness and Response Supplemental Appropriations Act H.R.6379, Take Responsibility for Workers and Families Act Relief for SUD treatment facilities and providers Telehealth Remote Recovery Support H.Res. 419, Resolution recognizing the contributions of the Addiction Profession workforce S. 2244, H.R. 413, Improving Access to Remote Behavioral Health Treatment Act The Comprehensive Addiction Resources Emergency (CARE) Act (S. 1365, H.R. 2569) The Parity Enforcement Act (HR 2848) The Behavioral Health Coverage Transparency Act (HR.2874, S.1576) Mental Health Parity Compliance Act (H.R.3165, S.1737) The Medicaid Reentry Act (H.R. 1329) S. 2412, the Addiction Treatment Access Act SUD privacy standards (42 CFR Part 2) H.R. 2062, The Overdose Prevention and Patient Safety Act Surprise Medical Billing compromise - timely billing and SUD parity Medication Assisted Treatment S.2974 - USPS Opioid & Illicit Drug Strategy Act of 2019 SUD Loan Repayment Program: Section 7071 of the Substance Use-Disorder Prevention that Promotes Opioid Recovery and Treatment (SUPPORT) for Patients and Communities Act (P.L. 115-271)

Client expense: Not reported · Firm income: $30,000

Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE

HR 3591 Campus Prevention and Recovery Services for Students Act of 2019 HR 2466 State Opioid Response Grant Authorization Act HR 2922 Respond Now Act HR 3849, S. 1204 Higher Education Mental Health Act of 2019 HR 3496, S. 1983 Create Opportunities Act HR 2569, S. 1365 Comprehensive Addiction Resources Emergency Act HR 3797 Medical Marijuana Research Act of 2019

Client expense: $230,000 · Firm income: Not reported

Government targets: Agency for Healthcare Research & Quality (AHRQ), Agriculture, Dept of (USDA), Centers For Disease Control & Prevention (CDC), Commerce, Dept of (DOC), Defense, Dept of (DOD), Education, Dept of, Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), Justice, Dept of (DOJ), Labor, Dept of (DOL), Natl Institute on Alcohol Abuse & Alcoholism (NIAA), Natl Institutes of Health (NIH), Natl Science Foundation (NSF), Natl Security Agency (NSA), Office of Natl Drug Control Policy (NDCP), SENATE, Substance Abuse & Mental Health Services Administration (SAMHSA), Veterans Affairs, Dept of (VA)

Drug overdose prevention, expanding access to drug treatment and harm reduction services. HR 2482/S 2074, the Medication Assisted Treatment Act; HR 2569/S 1365, Comprehensive Addiction Resources Emergency Act

Client expense: $87,644 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Opioids, pain management Federal funding for Substance Use Disorder treatments H.R.2281-Easy MAT for Opioid Addiction Act H.R.2482-Mainstreaming Addiction Treatment Act of 2019 H.R.2569-Comprehensive Addiction Resources Emergency Act of 2019 S.1365-Comprehensive Addiction Resources Emergency Act of 2019 S.2074-Mainstreaming Addiction Treatment Act of 2019

Client expense: $861,628 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Price transparency, out-of-network reimbursement of emergency medical services, surprise medical bills Opioids, pain management Federal funding for Substance Use Disorder treatments Drug Shortages H.R.501-Poison Center Network Enhancement Act of 2019 H.R.861-End Surprise Billing Act of 2019 H.R.1301-Mental Health Telemedicine Expansion Act H.R.1309-Workplace Violence Prevention for Health Care and Social Service Workers Act H.R.1418-Competitive Health Insurance Reform Act of 2019 H.R.1554-Resident Education Deferred Interest (REDI) Act H.R.1682-Improving Access to Medicare Coverage Act of 2019 H.R.1767-Excellence in Mental Health and Addiction Treatment Expansion Act H.R.2281-Easy MAT for Opioid Addiction Act H.R.2328-Reauthorizing and Extending Americas Community Health Act H.R.2464-End the Cycle of Violence Act of 2019 H.R.2482-Mainstreaming Addiction Treatment Act of 2019 H.R.2519-Improving Mental Health Access from the Emergency Department Act of 2019 H.R.2550-Prevent Blood Loss with Emergency Equipment Devices Act of 2019 H.R.2569-Comprehensive Addiction Resources Emergency Act of 2019 H.R.3107-Improving Seniors Timely Access to Care Act of 2019 H.R.3417-Beneficiary Education Tools, Telehealth, and Extenders Reauthorization Act of 2019 H.R.3502-Protecting People From Surprise Medical Bills Act H.R.3630-No Surprises Act H.R.3984-Health Care Safety Net Enhancement Act of 2019 H.R.4861-Effective Suicide Screening and Assessment in the Emergency Department Act of 2019 H.R.4932-Creating Opportunities Now for Necessary and Effective Care Technologies for Health Act of 2019 S.289-Rural Physician Workforce Production Act of 2019 S.299-Geriatrics Workforce Improvement Act S.350-Competitive Health Insurance Reform Act of 2019 S.618-Medicare Choices Empowerment and Protection Act S.753-Improving Access to Medicare Coverage Act of 2019 S.824-Excellence in Mental Health and Addiction Treatment Expansion Act S.851-Workplace Violence Prevention for Health Care and Social Service Workers Act S.1173-Emergency Medical Services for Children Program Reauthorization Act of 2019 S.1199-Poison Center Network Enhancement Act of 2019 S.1266-Protecting Patients from Surprise Medical Bills Act S.1334-Improving Mental Health Access from the Emergency Department S.1350-Good Samaritan Health Professionals Act of 2019 S.1365-Comprehensive Addiction Resources Emergency Act of 2019 S.1531-Stopping The Outrageous Practice of Surprise Medical Bills Act of 2019 S.1895-Lower Health Care Costs Act S.2074-Mainstreaming Addiction Treatment Act of 2019 S.2741-Creating Opportunities Now for Necessary and Effective Care Technologies (CONNECT) for Health Act of 2019 S.3006-Effective Suicide Screening and Assessment in the Emergency Department Act of 2019 S.3143-Magnet Injury Prevention Act

Client expense: $861,628 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Maternal and child health legislation,focusing on National Children's Study (ECHO), Zika preparedness, tobacco control, opioids legislation and neonatal abstinence syndrome (NAS), antibiotic resistance, environmental health, vaccination, newborn screening, Healthy Start, maternal mental health. Specific legislation includes: MOMMAs Act (H.R. 1897/S. 916, MOMs Act (S. 116),MOMMIES Act (H.R. 2602, S. 1343), Quality Care for Moms and Babies Act (H.R. 1551/S. 1960), Maternal CARE Act (H.R. 6698/S. 1600), The Healthy Maternity and Obstetric Medicine Act (Healthy MOM Act) (H.R. 2778/S. 1481), Rural Maternal and Obstetric Modernization of Services (MOMS) Act (S. 2373), the Maternal Outcomes Matter Act of 2019 (S. 2586), Healthy Maternity and Obstetric Medicine Act (H.R. 2778, S. 1481), H.R. 4995, Maternal Health Quality Improvement Act of 2019, H.R. 4996, Helping Medicaid Offer Maternity Services Act of 2019, Reversing the Youth Tobacco Epidemic Act (H.R. 2339), Public Health Funding Restoration Act (H.R. 3447, S. 1944), and the Comprehensive Addiction Resources Emergency CARE Act (H.R. 2569, S. 1365), Newborn Screening Saves Lives Reauthorization Act of 2019 (HR 2507/S. 2158), Traveling Parents Screening Consistency Act (HR 3246), and the Tobacco Tax Equity Act (S. 2517).

Client expense: $30,000 · Firm income: Not reported

Government targets: Agriculture, Dept of (USDA), Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Environmental Protection Agency (EPA), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), Internal Revenue Service (IRS), Labor, Dept of (DOL), Natl Institutes of Health (NIH), Postal Regulatory Commission, SENATE, Treasury, Dept of, U.S. Postal Service (USPS)

Drug overdose prevention, expanding access to drug treatment and harm reduction services. HR 2482/S 2074, the Medication Assisted Treatment Act; HR 2569/S 1365, Comprehensive Addiction Resources Emergency Act

Client expense: $87,644 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, SENATE

H.R. 447: Affordable and Safe Prescription Drug Importation Act - Provisions related to importation H.R. 478: Safe and Affordable Drugs from Canada Act of 2019 - Provisions related to importation H.R. 965: Creating and Restoring Equal Access to Equivalent Samples (CREATES) Act of 2019 - Provisions related to Risk Evaluation and Mitigation Strategies (REMS) and limited distribution systems H.R. 985: FAST Generics Act of 2019 - Provisions related to Risk Evaluation and Mitigation Strategies (REMS) and limited distribution systems H.R. 1093: Stop Price Gouging Act - Provisions related to prescription drug pricing H.R. 1478: Affordable Insulin Act of 2019 - Provisions related to importation H.R. 1506: Fair and Immediate Release (FAIR) of Generic Drugs Act - Provisions related to generic prescription drug approvals H.R. 1922: Restoring Access to Medication Act of 2019 - Provisions related to prescription drug access H.R. 2064: To amend title XI of the Social Security Act to require manufacturers of certain drugs, devices, biologicals, and medical supplies to report on product samples provided to certain health care providers, and for other purposes - Provisions related to prescription drug samples H.R. 2069: Stopping the Pharmaceutical Industry from Keeping Drugs Expensive (SPIKE) Act of 2019 - Provisions related to increases in the wholesale acquisition costs of prescription drugs H.R. 2087: Drug Price Transparency Act - Provisions related to prescription drug pricing and transparency H.R. 2113: Prescription Drug STAR Act - Provisions related to prescription drug pricing, reporting and product samples H.R. 2296: FAIR Drug Pricing Act of 2019 / More Efficient Tools to Realize Information for Consumers Act - Provisions related to prescription drug pricing and transparency H.R. 2376: Prescription Pricing for the People Act of 2019 - Provisions related to prescription drug pricing transparency and pharmacy benefit managers H.R. 2569: Comprehensive Addiction Resources Emergency Act of 2019 - Provisions related to opioid crisis response funding H.R. 2732: Lessening Addiction By Enhancing Labeling Opioids Act of 2019 - Provisions related to labeling of prescription drugs H.R. 2734: Safer Prescribing of Controlled Substances Act - Provisions related to the prescribing of prescription drugs H.R. 2917: Opioid Crisis Accountability Act of 2019 - Provisions related to prescription drug marketing H.R. 3223: Pharmacy Benefit Manager Accountability Study Act of 2019 - Provisions related to prescription drug pricing transparency and pharmacy benefit managers H.R. 3327: Drug Price Transparency for Medicare Patients Act of 2019 - Provisions related to direct-to-consumer prescription drug advertising H.R. 3415: Real-Time Beneficiary Drug Cost Bill - Provisions related to drug pricing transparency H.R. 3947: Competition Prescription Act of 2019 - Provisions related to prescription drug pricing, patents, and other provisions H.R. 4010: Emergency Access to Insulin Act of 2019 - Provisions related to prescription drug access programs H.R. 4106: Responsibility in Drug Advertising Act of 2019 - Provisions related to direct-to-consumer prescription drug advertising H.R. 4158: CURE High Drug Prices Act - Provisions related to prescription drug pricing and transparency H.R. 4439: Creating Hope Reauthorization Act - Provisions related to rare disease priority review vouchers H.R. 4538: Closing Loopholes for Orphan Drugs Act - Provisions related to 340B prescription drug exclusions H.R. 4633: Investing in Safety and Innovation Act of 2019 - Provisions related to FDA programs reauthorization H.R. 4640: Affordable Pricing for Taxpayer-Funded Prescription Drugs Act of 2019 - Provisions related to prescription drug pricing and negotiation H.R. 4667: Biomedical Innovation Expansion Act of 2019 - Provisions related to NIH programs reauthorization H.R. 4710: Pharmaceutical Independence Long-Term Readiness Reform Act - Provisions related to the supply chain H.R. 4711: No Tax Breaks for Drug Ads Act - Provisions related to direct-to-consumer prescription drug advertising H.R. 4812: Ensuring Compliance Against Drug Diversion Act of 2019 - Provisions related to registrations under the Controlled Substances Act H.R. 4814: Suspicious Order Identification Act of 2019 - Provisions related to reporting on distribution of controlled substances H.R. 4906: Insulin Price Reduction Act - Provisions related to prescription drug pricing and transparency H.R. 4963: Stop the Importation and Manufacturing of Synthetic Analogues Act of 2019 - Provisions related to synthetic analogues H.R. 5031: Medical Innovation Act of 2019 - Provisions related to prescription drug manufacturer taxation and supplemental fees H.R. 5198: Patients' Right to Know Their Medication Act of 2019 - Provisions related to prescription drug labeling H.R. 5239: Prescription Drug Price Reporting Act - Provisions related to prescription drug pricing transparency H.R. 5304: PBM Transparency in Prescription Drug Costs Act - Provisions related to prescription drug pricing transparency H.R. 5381: International Pharmaceutical Transparency Act of 2019 - Provisions related to prescription drug labeling H.R. 5382: To create a mechanism whereby insulin manufacturers may sell directly to consumers at current net prices - Provisions related to prescription drug pricing H.R. 5442: To amend title XXVII of the Public Health Service Act and title XVIII of the Social Security Act to require pharmacies to disclose any differential between the cost of a prescription drug based on whether certain individuals use prescription drug coverage to acquire such drug, and for other purposes - Provisions related to prescription drug pricing and transparency H.R. 5497: Conditional Approval Act - Provisions related to approval pathway S. 61: Safe and Affordable Drugs from Canada Act of 2019 - Provisions related to importation S. 73: End Taxpayer Subsidies for Drug Ads Act - Provisions related to direct-to-consumer prescription drug advertising S. 97: Affordable and Safe Prescription Drug Importation Act - Provisions related to importation S. 340: Creating and Restoring Equal Access to Equivalent Samples (CREATES) Act of 2019 - Provisions related to Risk Evaluation and Mitigation Strategies (REMS) and limited distribution systems S. 378: Stop Price Gouging Act - Provisions related to prescription drug pricing S. 474: Stopping the Pharmaceutical Industry from Keeping Drugs Expensive (SPIKE) Act of 2019 - Provisions related to increases in the wholesale acquisition costs of prescription drugs S. 637: Combatting Unreasonable Rises and Excessively (CURE) High Drug Prices Act - Provisions related to prescription drug pricing and transparency S. 657: Drug Price Transparency Act - Provisions related to prescription drug pricing transparency and commercial market rebates S. 660: Efficiency and Transparency in Petitions Act - Provisions related to the FDA citizen petition process S. 1140: Protecting Access to Biosimilars Act of 2019 - Provisions related to biological products S. 1227: Prescription Pricing for the People Act of 2019 - Provisions related to prescription drug pricing transparency and pharmacy benefit managers S. 1250: American Cures Act - Provisions related to pharmaceutical research and development S. 1391: FAIR Drug Pricing Act of 2019 - Provisions related to prescription drug pricing and transparency S. 1437: Drug-price Transparency in Communications (DTC) Act - Provisions related to direct-to-consumer prescription drug advertising S. 1532: Pharmacy Benefit Manager Accountability Study Act of 2019 - Provisions related to prescription drug pricing transparency and pharmacy benefit managers S. 2004: Emergency Access to Insulin Act of 2019 - Provisions related to prescription drug pricing S. 2103: Affordable Insulin Approvals Now Act - Provisions related to FDA prescription drug approvals S. 2161: Reciprocity Ensures Streamlined Use of Lifesaving Treatments Act of 2019 - Provisions related to reciprocity S. 2199: Insulin Price Reduction Act - Provisions related to prescription drug pricing and transparency S. 2723: Mitigating Emergency Drug Shortages Act - Provisions related to prescription drug pricing transparency and other provisions S. 2897: Patient-Centered Outcomes Research Institute Reauthorization Act - Provisions related to PCORI reauthorization Transparency policy issues Drug cost and pricing policy issues Drug importation and counterfeiting policy issues HHS Safe Importation Action Plan Prescription drug take back and secure disposal policy issues Policy issues related to prescription drug abuse and opioids Expanded access policy issues Generic drug approval process policy issues High deductible health plans/HSA policy issues Sharing of truthful and non-misleading information about medicines with healthcare professionals and payors Risk Evaluation and Mitigation Strategy (REMS) policy issues FDA modernization policy issues PDUFA implementation policy issues 340B drug discount program policy issues Bipartisan Budget Act of 2018 (Public Law 115-123) - Part D provisions Patient assistance program policy issues Foreign manufacturing policy issues Biosimilar approval and reimbursement policy issues Drug compounding policy issues including federal oversight of compounded drugs Cancer drug vial size policy issues TRICARE pharmacy pilot program Drug shortages policy issues Request for Information: HHS Blueprint to Lower Drug Prices and Reduce Out-of-Pocket Costs (RIN 0991-ZA49) Proposed Rule; Importation of Prescription Drugs (RIN 0910-AI45)

Client expense: $6,450,000 · Firm income: Not reported

Government targets: Centers For Medicare and Medicaid Services (CMS), Executive Office of the President (EOP), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Economic Council (NEC), Office of Management & Budget (OMB), Office of the Vice President of the United States, Patent & Trademark Office (PTO), SENATE, U.S. Trade Representative (USTR)

Teaching Health Centers; Health Information Technology and TeleHealth; Substance abuse and opioid use; 340B Drug Discount Program; Title X Program, Training the Next Generation of Primary Care Doctors(S.304/H.R.2815); Funding for School-Based Health Centers(S.1365/H.R.2569); Lower Drug Costs Now Act of 2019 (H.R. 3).

Client expense: $210,000 · Firm income: Not reported

Government targets: Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, Health Resources & Services Administration (HRSA), Office of Management & Budget (OMB), SENATE, White House Office

The Special Registration for Telemedicine Clarification Act (H.R. 5483 (115)), all provisions related to establishing a special registration process with the Drug Enforcement Agency (DEA) for certain providers that wish to prescribe controlled substances via telemedicine. Mainstreaming Addiction Treatment Act (S. 2074/H.R. 2482), all provisions related to removing the waiver requirement for health care providers to prescribe buprenorphine for opioid use disorder. National Suicide Hotline Designation Act of 2019 (H.R. 4194), all provisions related to requiring the Federal Communications Commission designate 9-8-8 as a universal national suicide prevention and mental health crisis hotline number. Improving Access to Remote Behavioral Health Treatment Act of 2019 (S. 2244/H.R. 4131), all provisions related to amending regulations for the Ryan Haight Online Pharmacy Consumer Protection Act of 2008 and allowing community mental health centers to register to practice telemedicine. Comprehensive Addiction Resources Emergency Act of 2019 (S. 1365/H.R. 2569), all provisions related to providing emergency assistance to areas affected by the opioid epidemic, as well as grant funding for substance use disorder treatment research. Mental Health Parity Compliance Act (S. 1737/H.R. 3165), all provisions related to strengthening parity for mental health and substance use disorder benefits. Effective Suicide Screening and Assessment in the Emergency Department Act of 2019 (S. 3006/H.R. 4861), all provisions related to establishing a program to improve identification, assessment, and treatment of patients in the emergency department who are at risk of suicide. Behavioral Health Coverage Transparency Act (S. 1576/H.R. 2874), all provisions related to strengthening parity for mental health and substance use disorder benefits. Medication Access and Training Expansion Act of 2019 (H.R. 4974), all provisions related to prescriber training on treating patients with opioid and other substance use disorders. Resilience Investment, Support and Expansion from Trauma Act (S. 1770/H.R. 3180), all provisions related to supporting children and families who experience trauma. Barriers to Suicide Act of 2019 (H.R. 4309), all provisions related to establishing a grant program to install suicide deterrents. Mental Health Professionals Workforce Shortage Loan Repayment Act of 2019 (S. 2500/H.R. 2431), all provisions related to authorizing a loan repayment program for mental health professionals. Parity Enforcement Act of 2019 (H.R. 2848), all provisions related to strengthening parity for mental health and substance use disorder benefits. Protecting Pre-Existing Conditions and Making Health Care More Affordable Act of 2019 (H.R. 1884), all provisions related to improving affordability of and increasing access to health insurance coverage. Mental Health Services for Students Act of 2019 (S. 1122), all provisions related to providing access to school-based comprehensive mental health programs. CREATE Opportunities Act (S. 1983/H.R. 3496), all provisions related to providing medication-assisted treatment to individuals with opioid use disorder and are incarcerated. Primary and Behavioral Health Care Access Act (H.R. 5575), all provisions related to requiring group health plans and health insurance issuers to provide for primary and behavioral health care visits without cost-sharing.

Client expense: $68,150 · Firm income: Not reported

Government targets: Drug Enforcement Administration (DEA), Federal Communications Commission (FCC), HOUSE OF REPRESENTATIVES, SENATE

Advocated for FY2020 Labor HHS Appropriations bill - appropriations related to strengthening the addiction services workforce, including full funding of the loan repayment program for the substance use disorder treatment workforce authorized in the SUPPORT Act, the mental and substance use disorders training demonstration program authorized in 21st Century Cures Act, and preventive medicine residency programs; report language regarding national standards for treatment programs Supported HR 3496 & S 1983 CREATE Opportunities Act - grants to, and cooperative agreements with, state and local governments to develop, implement, or expand medication-assisted treatment for incarcerated individuals who are addicted to opioids. Supported HR 2569 & S 1365 - Comprehensive Addiction Resources Emergency Act - to provide emergency assistance to States, territories, Tribal nations, and local areas affected by the opioid epidemic and to make financial assistance available to States, territories, Tribal nations, local areas, and public or private nonprofit entities to provide for the development, organization, coordination, and operation of more effective and cost efficient systems for the delivery of essential services to individuals with substance use disorder and their families. Advocated for additional evidence-based standards. Supported HR 3414 (and prior versions)/ S. 2892 - Opioid Workforce Act of 2019 - bill increases the number of residency positions eligible for graduate medical education payments under Medicare for hospitals that have addiction or pain management programs, with an aggregate increase of 1,000 positions over a five-year period. Supported HR 3165 and S 1737 - Mental Health Parity Compliance Act - strengthen parity in mental health and substance use disorder benefits. Advocated for its inclusion in the Lower Health Care Costs Act of 2019. Supported S 873 and HR 1879 - Stabilize Medicaid and CHIP Coverage Act which would provide for 12 months of continuous enrollment in Medicaid and CHIP to ensure better access to care and reduce churn. This bill is not specific to mental health, but it would provide significant stability to those patients and providers. Supported H.R.2062/S. 1012 - To amend the Public Health Service Act to protect the confidentiality of substance use disorder patient records. Supported H.R.1920 - Medicaid Bump Act - To amend title XIX of the Social Security Act to provide a higher Federal matching rate for increased expenditures under Medicaid for mental and behavioral health services, and for other purposes. Supported H.R.1329 - Medicaid Reentry Act - This bill allows Medicaid payment for medical services furnished to an incarcerated individual during the 30-day period preceding the individual's release. Supported S 824/HR 1767 - Excellence in Mental Health and Addiction Treatment Expansion Act This legislation would extend and expand the Certified Community Behavioral Health Clinic (CCBHC) demonstration, which is set to end in mid-2019. Supported the Parity Enforcement Act (HR 2848). This legislation would give the U.S. Department of Labor authority to levy civil monetary penalties against health insurers and plan sponsors for parity violations of the Paul Wellstone and Pete Domenici Mental Health Parity and Addiction Equity Act of 2008. Supported HR 2734/S 1448 - Safer Prescribing of Controlled Substances Act. The bill calls for mandatory education for practitioners licensed to dispense or conduct research with controlled substances in schedule II, III, IV, or V. The education, which would be required as part of a prescribers DEA licensure registration and renewal, will focus on best practices for pain management and alternative non-opioid therapies for pain, methods for diagnosing and treating a substance use disorder, linking patients to evidence-based treatment for substance use disorder, and tools to manage adherence and diversion of controlled substances, including Prescription Drug Monitoring Programs. Supported S.1012/ HR 2062 Protecting Jessica Grubbs Legacy Act/ Overdose Prevention and Patient Safety Act to amend the Public Health Service Act to protect the confidentiality of substance use disorder patient records. Supported HR 4974: the MATE Act - to amend the Controlled Substances Act to require physicians and other prescribers of controlled substances to complete training on treating and managing patients with opioid and other substance use disorders (which shall also satisfy certain training required to receive a waiver for dispensing narcotic drugs for maintenance or detoxification treatment),and for other purposes. Advocated for reduction of barriers to buprenorphine related to treatment of hospitalized patients. Supported the Marijuana and Cannabidiol Research Expansion Act. This legislation would enable the expansion of the scientific research base on marijuana to answer critical questions, such as identifying potential therapeutic effects and possible public health consequences. Supported the Medical Marijuana Research Act of 2019, which would reduce many of the burdensome barriers researchers face when conducting legitimate scientific research involving cannabis. The bill would ensure that a supply of cannabis is continuously available to researchers, streamline various cannabis related application processes that run through the Department of Justice, and require the Department of Health and Human Services to conduct a review of existing research on cannabis. Supported a conditional endorsement of The Mainstreaming Addiction Treatment Act, which is contingent upon the elimination of DEA regulations on medications in Schedules III-V that are based on the prescribing intent to treat addiction and a requirement that all DEA controlled substance prescribers complete medical education on addiction. Supported the Humane Correctional Health Care Act , H.R. 4141/S. 2305, which would repeal the Medicaid Inmate Exclusion. The exclusion strips health coverage from Medicaid enrollees who are involved in the criminal justice system. Supported H.R. 3925, the Reducing Barriers to Substance Use Treatment Act, introduced by Representatives Paul Tonko (D-NY) and David McKinley (R-VA). The bill would prohibit state Medicaid programs, beginning in October 1, 2020, and ending September 30, 2025, from imposing prior authorizations or other types of utilization control policies or procedures on medications approved to treat OUD, including, with respect to the provision of those medications, counseling services and behavioral therapy. Support the Stopping Appealing Flavors in E-Cigarettes for Kids Act (SAFE Kids Act), introduced by Senator Dick Durbin and Senator Lisa Murkowski (S. 655) and Representative Diana DeGette and Representative Jamie Raskin (H.R. 1498). The bill would prohibit flavors in e-cigarettes unless the manufacturer demonstrates that a flavor will help with smoking cessation, not increase youth initiation, and not increase the risk of harm to the user. It furthermore prohibits use of flavors in other non-cigarette tobacco products, such as cigars and smokeless tobacco. Opposed the Traditional Cigar Manufacturing and Small Business Jobs Preservation Act of 2019, which would prohibit FDA from promulgating any public health protections related to what the cigar industry calls traditional large and premium cigars. Even the most basic Food and Drug Administration (FDA) requirements like ingredient disclosure and warning labels as well as enforcement of youth access laws would not apply to these products. Supported the Reversing the Youth Tobacco Epidemic Act of 2019 (HR 2339) which would, among other things, amend the Federal Food, Drug, and Cosmetic Act with respect to the sale and marketing of tobacco products Submitted comments on amendments to regulations under the Federal anti-kickback statute (AKS). The proposed amendments would modify and add new safe harbors under the statute and exceptions to the beneficiary inducements civil monetary penalty definition of remuneration to foster arrangements that would promote care coordination and advance the delivery of value-based care while also protecting patients and taxpayer dollars against harms caused by fraud and abuse. Supported H.Res. 714: Recognizing addiction as a disease and supporting efforts to prevent, treat, and destigmatize substance use disorder and addiction. Submitted a response to a request for information (RFI) regarding substance use disorder (SUD) treatment by Representatives Greg Walden, Michael Burgess, and Brett Guthrie, Republican leaders of the House Committee on Energy and Commerce. The RFI focused on challenges, failures, fraud and abuse within the SUD treatment industry, as well as opportunities to improve the quality of treatment. Provided comments to ONDCP regarding next National Drug Control Strategy per invitation, focusing on addiction treatment workforce, setting standards, monitoring program effectiveness, coverage for addiction treatment services.

Client expense: $70,000 · Firm income: Not reported

Government targets: Drug Enforcement Administration (DEA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Office of Natl Drug Control Policy (NDCP), SENATE

Advocated for FY2020 Labor HHS Appropriations bill - appropriations related to strengthening the addiction services workforce, including full funding of the loan repayment program for the substance use disorder treatment workforce authorized in the SUPPORT Act, the mental and substance use disorders training demonstration program authorized in 21st Century Cures Act, and preventive medicine residency programs; report language regarding national standards for treatment programs Supported HR 3496 & S 1983 CREATE Opportunities Act - grants to, and cooperative agreements with, state and local governments to develop, implement, or expand medication-assisted treatment for incarcerated individuals who are addicted to opioids. Supported HR 2569 & S 1365 - Comprehensive Addiction Resources Emergency Act - to provide emergency assistance to States, territories, Tribal nations, and local areas affected by the opioid epidemic and to make financial assistance available to States, territories, Tribal nations, local areas, and public or private nonprofit entities to provide for the development, organization, coordination, and operation of more effective and cost efficient systems for the delivery of essential services to individuals with substance use disorder and their families. Advocated for additional evidence-based standards. Supported HR 3414 (and prior versions)/ S. 2892 - Opioid Workforce Act of 2019 - bill increases the number of residency positions eligible for graduate medical education payments under Medicare for hospitals that have addiction or pain management programs, with an aggregate increase of 1,000 positions over a five-year period. Supported HR 3165 and S 1737 - Mental Health Parity Compliance Act - strengthen parity in mental health and substance use disorder benefits. Advocated for its inclusion in the Lower Health Care Costs Act of 2019. Supported S 873 and HR 1879 - Stabilize Medicaid and CHIP Coverage Act which would provide for 12 months of continuous enrollment in Medicaid and CHIP to ensure better access to care and reduce churn. This bill is not specific to mental health, but it would provide significant stability to those patients and providers. Supported H.R.2062/S. 1012 - To amend the Public Health Service Act to protect the confidentiality of substance use disorder patient records. Supported H.R.1920 - Medicaid Bump Act - To amend title XIX of the Social Security Act to provide a higher Federal matching rate for increased expenditures under Medicaid for mental and behavioral health services, and for other purposes. Supported H.R.1329 - Medicaid Reentry Act - This bill allows Medicaid payment for medical services furnished to an incarcerated individual during the 30-day period preceding the individual's release. Supported S 824/HR 1767 - Excellence in Mental Health and Addiction Treatment Expansion Act This legislation would extend and expand the Certified Community Behavioral Health Clinic (CCBHC) demonstration, which is set to end in mid-2019. Supported the Parity Enforcement Act (HR 2848). This legislation would give the U.S. Department of Labor authority to levy civil monetary penalties against health insurers and plan sponsors for parity violations of the Paul Wellstone and Pete Domenici Mental Health Parity and Addiction Equity Act of 2008. Supported HR 2734/S 1448 - Safer Prescribing of Controlled Substances Act. The bill calls for mandatory education for practitioners licensed to dispense or conduct research with controlled substances in schedule II, III, IV, or V. The education, which would be required as part of a prescribers DEA licensure registration and renewal, will focus on best practices for pain management and alternative non-opioid therapies for pain, methods for diagnosing and treating a substance use disorder, linking patients to evidence-based treatment for substance use disorder, and tools to manage adherence and diversion of controlled substances, including Prescription Drug Monitoring Programs. Supported S.1012/ HR 2062 Protecting Jessica Grubbs Legacy Act/ Overdose Prevention and Patient Safety Act to amend the Public Health Service Act to protect the confidentiality of substance use disorder patient records. Supported HR 4974: the MATE Act - to amend the Controlled Substances Act to require physicians and other prescribers of controlled substances to complete training on treating and managing patients with opioid and other substance use disorders (which shall also satisfy certain training required to receive a waiver for dispensing narcotic drugs for maintenance or detoxification treatment),and for other purposes. Supported the Marijuana and Cannabidiol Research Expansion Act. This legislation would enable the expansion of the scientific research base on marijuana to answer critical questions, such as identifying potential therapeutic effects and possible public health consequences. Supported the Medical Marijuana Research Act of 2019, which would reduce many of the burdensome barriers researchers face when conducting legitimate scientific research involving cannabis. The bill would ensure that a supply of cannabis is continuously available to researchers, streamline various cannabis related application processes that run through the Department of Justice, and require the Department of Health and Human Services to conduct a review of existing research on cannabis. Supported a conditional endorsement of The Mainstreaming Addiction Treatment Act, which is contingent upon the elimination of DEA regulations on medications in Schedules III-V that are based on the prescribing intent to treat addiction and a requirement that all DEA controlled substance prescribers complete medical education on addiction. Supported the Humane Correctional Health Care Act , H.R. 4141/S. 2305, which would repeal the Medicaid Inmate Exclusion. The exclusion strips health coverage from Medicaid enrollees who are involved in the criminal justice system. Supported H.R. 3925, the Reducing Barriers to Substance Use Treatment Act, introduced by Representatives Paul Tonko (D-NY) and David McKinley (R-VA). The bill would prohibit state Medicaid programs, beginning in October 1, 2020, and ending September 30, 2025, from imposing prior authorizations or other types of utilization control policies or procedures on medications approved to treat OUD, including, with respect to the provision of those medications, counseling services and behavioral therapy. Support the Stopping Appealing Flavors in E-Cigarettes for Kids Act (SAFE Kids Act), introduced by Senator Dick Durbin and Senator Lisa Murkowski (S. 655) and Representative Diana DeGette and Representative Jamie Raskin (H.R. 1498). The bill would prohibit flavors in e-cigarettes unless the manufacturer demonstrates that a flavor will help with smoking cessation, not increase youth initiation, and not increase the risk of harm to the user. It furthermore prohibits use of flavors in other non-cigarette tobacco products, such as cigars and smokeless tobacco. Opposed the Traditional Cigar Manufacturing and Small Business Jobs Preservation Act of 2019, which would prohibit FDA from promulgating any public health protections related to what the cigar industry calls traditional large and premium cigars. Even the most basic Food and Drug Administration (FDA) requirements like ingredient disclosure and warning labels as well as enforcement of youth access laws would not apply to these products. Supported the Reversing the Youth Tobacco Epidemic Act of 2019 (HR 2339) which would, among other things, amend the Federal Food, Drug, and Cosmetic Act with respect to the sale and marketing of tobacco products Submitted comments on amendments to regulations under the Federal anti-kickback statute (AKS). The proposed amendments would modify and add new safe harbors under the statute and exceptions to the beneficiary inducements civil monetary penalty definition of remuneration to foster arrangements that would promote care coordination and advance the delivery of value-based care while also protecting patients and taxpayer dollars against harms caused by fraud and abuse. Supported H.Res. 714: Recognizing addiction as a disease and supporting efforts to prevent, treat, and destigmatize substance use disorder and addiction. Submitted a response to a request for information (RFI) regarding substance use disorder (SUD) treatment by Representatives Greg Walden, Michael Burgess, and Brett Guthrie, Republican leaders of the House Committee on Energy and Commerce. The RFI focused on challenges, failures, fraud and abuse within the SUD treatment industry, as well as opportunities to improve the quality of treatment. Provided comments to ONDCP regarding next National Drug Control Strategy per invitation, focusing on addiction treatment workforce, setting standards, monitoring program effectiveness, coverage for addiction treatment services.

Client expense: $70,000 · Firm income: Not reported

Government targets: Drug Enforcement Administration (DEA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Office of Natl Drug Control Policy (NDCP), SENATE

Advocated for FY2020 Labor HHS Appropriations bill - appropriations related to strengthening the addiction services workforce, including full funding of the loan repayment program for the substance use disorder treatment workforce authorized in the SUPPORT Act, the mental and substance use disorders training demonstration program authorized in 21st Century Cures Act, and preventive medicine residency programs; report language regarding national standards for treatment programs Supported HR 3496 & S 1983 CREATE Opportunities Act - grants to, and cooperative agreements with, state and local governments to develop, implement, or expand medication-assisted treatment for incarcerated individuals who are addicted to opioids. Supported HR 2569 & S 1365 - Comprehensive Addiction Resources Emergency Act - to provide emergency assistance to States, territories, Tribal nations, and local areas affected by the opioid epidemic and to make financial assistance available to States, territories, Tribal nations, local areas, and public or private nonprofit entities to provide for the development, organization, coordination, and operation of more effective and cost efficient systems for the delivery of essential services to individuals with substance use disorder and their families. Advocated for additional evidence-based standards. Supported HR 3414 (and prior versions)/ S. 2892 - Opioid Workforce Act of 2019 - bill increases the number of residency positions eligible for graduate medical education payments under Medicare for hospitals that have addiction or pain management programs, with an aggregate increase of 1,000 positions over a five-year period. Supported HR 3165 and S 1737 - Mental Health Parity Compliance Act - strengthen parity in mental health and substance use disorder benefits. Advocated for its inclusion in the Lower Health Care Costs Act of 2019. Supported S 873 and HR 1879 - Stabilize Medicaid and CHIP Coverage Act which would provide for 12 months of continuous enrollment in Medicaid and CHIP to ensure better access to care and reduce churn. This bill is not specific to mental health, but it would provide significant stability to those patients and providers. Supported H.R.2062/S. 1012 - To amend the Public Health Service Act to protect the confidentiality of substance use disorder patient records. Supported H.R.1920 - Medicaid Bump Act - To amend title XIX of the Social Security Act to provide a higher Federal matching rate for increased expenditures under Medicaid for mental and behavioral health services, and for other purposes. Supported H.R.1329 - Medicaid Reentry Act - This bill allows Medicaid payment for medical services furnished to an incarcerated individual during the 30-day period preceding the individual's release. Supported S 824/HR 1767 - Excellence in Mental Health and Addiction Treatment Expansion Act This legislation would extend and expand the Certified Community Behavioral Health Clinic (CCBHC) demonstration, which is set to end in mid-2019. Supported the Parity Enforcement Act (HR 2848). This legislation would give the U.S. Department of Labor authority to levy civil monetary penalties against health insurers and plan sponsors for parity violations of the Paul Wellstone and Pete Domenici Mental Health Parity and Addiction Equity Act of 2008. Supported HR 2734/S 1448 - Safer Prescribing of Controlled Substances Act. The bill calls for mandatory education for practitioners licensed to dispense or conduct research with controlled substances in schedule II, III, IV, or V. The education, which would be required as part of a prescribers DEA licensure registration and renewal, will focus on best practices for pain management and alternative non-opioid therapies for pain, methods for diagnosing and treating a substance use disorder, linking patients to evidence-based treatment for substance use disorder, and tools to manage adherence and diversion of controlled substances, including Prescription Drug Monitoring Programs. Supported S.1012/ HR 2062 Protecting Jessica Grubbs Legacy Act/ Overdose Prevention and Patient Safety Act to amend the Public Health Service Act to protect the confidentiality of substance use disorder patient records. Supported HR 4974: the MATE Act - to amend the Controlled Substances Act to require physicians and other prescribers of controlled substances to complete training on treating and managing patients with opioid and other substance use disorders (which shall also satisfy certain training required to receive a waiver for dispensing narcotic drugs for maintenance or detoxification treatment),and for other purposes. Advocated for reduction of barriers to buprenorphine related to treatment of hospitalized patients. Supported the Marijuana and Cannabidiol Research Expansion Act. This legislation would enable the expansion of the scientific research base on marijuana to answer critical questions, such as identifying potential therapeutic effects and possible public health consequences. Supported the Medical Marijuana Research Act of 2019, which would reduce many of the burdensome barriers researchers face when conducting legitimate scientific research involving cannabis. The bill would ensure that a supply of cannabis is continuously available to researchers, streamline various cannabis related application processes that run through the Department of Justice, and require the Department of Health and Human Services to conduct a review of existing research on cannabis. Supported a conditional endorsement of The Mainstreaming Addiction Treatment Act, which is contingent upon the elimination of DEA regulations on medications in Schedules III-V that are based on the prescribing intent to treat addiction and a requirement that all DEA controlled substance prescribers complete medical education on addiction. Supported the Humane Correctional Health Care Act , H.R. 4141/S. 2305, which would repeal the Medicaid Inmate Exclusion. The exclusion strips health coverage from Medicaid enrollees who are involved in the criminal justice system. Supported H.R. 3925, the Reducing Barriers to Substance Use Treatment Act, introduced by Representatives Paul Tonko (D-NY) and David McKinley (R-VA). The bill would prohibit state Medicaid programs, beginning in October 1, 2020, and ending September 30, 2025, from imposing prior authorizations or other types of utilization control policies or procedures on medications approved to treat OUD, including, with respect to the provision of those medications, counseling services and behavioral therapy. Support the Stopping Appealing Flavors in E-Cigarettes for Kids Act (SAFE Kids Act), introduced by Senator Dick Durbin and Senator Lisa Murkowski (S. 655) and Representative Diana DeGette and Representative Jamie Raskin (H.R. 1498). The bill would prohibit flavors in e-cigarettes unless the manufacturer demonstrates that a flavor will help with smoking cessation, not increase youth initiation, and not increase the risk of harm to the user. It furthermore prohibits use of flavors in other non-cigarette tobacco products, such as cigars and smokeless tobacco. Opposed the Traditional Cigar Manufacturing and Small Business Jobs Preservation Act of 2019, which would prohibit FDA from promulgating any public health protections related to what the cigar industry calls traditional large and premium cigars. Even the most basic Food and Drug Administration (FDA) requirements like ingredient disclosure and warning labels as well as enforcement of youth access laws would not apply to these products. Supported the Reversing the Youth Tobacco Epidemic Act of 2019 (HR 2339) which would, among other things, amend the Federal Food, Drug, and Cosmetic Act with respect to the sale and marketing of tobacco products Submitted comments on amendments to regulations under the Federal anti-kickback statute (AKS). The proposed amendments would modify and add new safe harbors under the statute and exceptions to the beneficiary inducements civil monetary penalty definition of remuneration to foster arrangements that would promote care coordination and advance the delivery of value-based care while also protecting patients and taxpayer dollars against harms caused by fraud and abuse. Supported H.Res. 714: Recognizing addiction as a disease and supporting efforts to prevent, treat, and destigmatize substance use disorder and addiction. Submitted a response to a request for information (RFI) regarding substance use disorder (SUD) treatment by Representatives Greg Walden, Michael Burgess, and Brett Guthrie, Republican leaders of the House Committee on Energy and Commerce. The RFI focused on challenges, failures, fraud and abuse within the SUD treatment industry, as well as opportunities to improve the quality of treatment. Provided comments to ONDCP regarding next National Drug Control Strategy per invitation, focusing on addiction treatment workforce, setting standards, monitoring program effectiveness, coverage for addiction treatment services.

Client expense: $70,000 · Firm income: Not reported

Government targets: Drug Enforcement Administration (DEA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Office of Natl Drug Control Policy (NDCP), SENATE

Advocated for FY2020 Labor HHS Appropriations bill - appropriations related to strengthening the addiction services workforce, including full funding of the loan repayment program for the substance use disorder treatment workforce authorized in the SUPPORT Act, the mental and substance use disorders training demonstration program authorized in 21st Century Cures Act, and preventive medicine residency programs; report language regarding national standards for treatment programs Supported HR 3496 & S 1983 CREATE Opportunities Act - grants to, and cooperative agreements with, state and local governments to develop, implement, or expand medication-assisted treatment for incarcerated individuals who are addicted to opioids. Supported HR 2569 & S 1365 - Comprehensive Addiction Resources Emergency Act - to provide emergency assistance to States, territories, Tribal nations, and local areas affected by the opioid epidemic and to make financial assistance available to States, territories, Tribal nations, local areas, and public or private nonprofit entities to provide for the development, organization, coordination, and operation of more effective and cost efficient systems for the delivery of essential services to individuals with substance use disorder and their families. Advocated for additional evidence-based standards. Supported HR 3414 (and prior versions)/ S. 2892 - Opioid Workforce Act of 2019 - bill increases the number of residency positions eligible for graduate medical education payments under Medicare for hospitals that have addiction or pain management programs, with an aggregate increase of 1,000 positions over a five-year period. Supported HR 3165 and S 1737 - Mental Health Parity Compliance Act - strengthen parity in mental health and substance use disorder benefits. Advocated for its inclusion in the Lower Health Care Costs Act of 2019. Supported S 873 and HR 1879 - Stabilize Medicaid and CHIP Coverage Act which would provide for 12 months of continuous enrollment in Medicaid and CHIP to ensure better access to care and reduce churn. This bill is not specific to mental health, but it would provide significant stability to those patients and providers. Supported H.R.2062/S. 1012 - To amend the Public Health Service Act to protect the confidentiality of substance use disorder patient records. Supported H.R.1920 - Medicaid Bump Act - To amend title XIX of the Social Security Act to provide a higher Federal matching rate for increased expenditures under Medicaid for mental and behavioral health services, and for other purposes. Supported H.R.1329 - Medicaid Reentry Act - This bill allows Medicaid payment for medical services furnished to an incarcerated individual during the 30-day period preceding the individual's release. Supported S 824/HR 1767 - Excellence in Mental Health and Addiction Treatment Expansion Act This legislation would extend and expand the Certified Community Behavioral Health Clinic (CCBHC) demonstration, which is set to end in mid-2019. Supported the Parity Enforcement Act (HR 2848). This legislation would give the U.S. Department of Labor authority to levy civil monetary penalties against health insurers and plan sponsors for parity violations of the Paul Wellstone and Pete Domenici Mental Health Parity and Addiction Equity Act of 2008. Supported HR 2734/S 1448 - Safer Prescribing of Controlled Substances Act. The bill calls for mandatory education for practitioners licensed to dispense or conduct research with controlled substances in schedule II, III, IV, or V. The education, which would be required as part of a prescribers DEA licensure registration and renewal, will focus on best practices for pain management and alternative non-opioid therapies for pain, methods for diagnosing and treating a substance use disorder, linking patients to evidence-based treatment for substance use disorder, and tools to manage adherence and diversion of controlled substances, including Prescription Drug Monitoring Programs. Supported S.1012/ HR 2062 Protecting Jessica Grubbs Legacy Act/ Overdose Prevention and Patient Safety Act to amend the Public Health Service Act to protect the confidentiality of substance use disorder patient records. Supported HR 4974: the MATE Act - to amend the Controlled Substances Act to require physicians and other prescribers of controlled substances to complete training on treating and managing patients with opioid and other substance use disorders (which shall also satisfy certain training required to receive a waiver for dispensing narcotic drugs for maintenance or detoxification treatment),and for other purposes. Supported the Marijuana and Cannabidiol Research Expansion Act. This legislation would enable the expansion of the scientific research base on marijuana to answer critical questions, such as identifying potential therapeutic effects and possible public health consequences. Supported the Medical Marijuana Research Act of 2019, which would reduce many of the burdensome barriers researchers face when conducting legitimate scientific research involving cannabis. The bill would ensure that a supply of cannabis is continuously available to researchers, streamline various cannabis related application processes that run through the Department of Justice, and require the Department of Health and Human Services to conduct a review of existing research on cannabis. Supported a conditional endorsement of The Mainstreaming Addiction Treatment Act, which is contingent upon the elimination of DEA regulations on medications in Schedules III-V that are based on the prescribing intent to treat addiction and a requirement that all DEA controlled substance prescribers complete medical education on addiction. Supported the Humane Correctional Health Care Act , H.R. 4141/S. 2305, which would repeal the Medicaid Inmate Exclusion. The exclusion strips health coverage from Medicaid enrollees who are involved in the criminal justice system. Supported H.R. 3925, the Reducing Barriers to Substance Use Treatment Act, introduced by Representatives Paul Tonko (D-NY) and David McKinley (R-VA). The bill would prohibit state Medicaid programs, beginning in October 1, 2020, and ending September 30, 2025, from imposing prior authorizations or other types of utilization control policies or procedures on medications approved to treat OUD, including, with respect to the provision of those medications, counseling services and behavioral therapy. Support the Stopping Appealing Flavors in E-Cigarettes for Kids Act (SAFE Kids Act), introduced by Senator Dick Durbin and Senator Lisa Murkowski (S. 655) and Representative Diana DeGette and Representative Jamie Raskin (H.R. 1498). The bill would prohibit flavors in e-cigarettes unless the manufacturer demonstrates that a flavor will help with smoking cessation, not increase youth initiation, and not increase the risk of harm to the user. It furthermore prohibits use of flavors in other non-cigarette tobacco products, such as cigars and smokeless tobacco. Opposed the Traditional Cigar Manufacturing and Small Business Jobs Preservation Act of 2019, which would prohibit FDA from promulgating any public health protections related to what the cigar industry calls traditional large and premium cigars. Even the most basic Food and Drug Administration (FDA) requirements like ingredient disclosure and warning labels as well as enforcement of youth access laws would not apply to these products. Supported the Reversing the Youth Tobacco Epidemic Act of 2019 (HR 2339) which would, among other things, amend the Federal Food, Drug, and Cosmetic Act with respect to the sale and marketing of tobacco products Submitted comments on amendments to regulations under the Federal anti-kickback statute (AKS). The proposed amendments would modify and add new safe harbors under the statute and exceptions to the beneficiary inducements civil monetary penalty definition of remuneration to foster arrangements that would promote care coordination and advance the delivery of value-based care while also protecting patients and taxpayer dollars against harms caused by fraud and abuse. Supported H.Res. 714: Recognizing addiction as a disease and supporting efforts to prevent, treat, and destigmatize substance use disorder and addiction. Submitted a response to a request for information (RFI) regarding substance use disorder (SUD) treatment by Representatives Greg Walden, Michael Burgess, and Brett Guthrie, Republican leaders of the House Committee on Energy and Commerce. The RFI focused on challenges, failures, fraud and abuse within the SUD treatment industry, as well as opportunities to improve the quality of treatment. Provided comments to ONDCP regarding next National Drug Control Strategy per invitation, focusing on addiction treatment workforce, setting standards, monitoring program effectiveness, coverage for addiction treatment services.

Client expense: $70,000 · Firm income: Not reported

Government targets: Drug Enforcement Administration (DEA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Office of Natl Drug Control Policy (NDCP), SENATE

Advocated for FY2020 Labor HHS Appropriations bill - appropriations related to strengthening the addiction services workforce, including full funding of the loan repayment program for the substance use disorder treatment workforce authorized in the SUPPORT Act, the mental and substance use disorders training demonstration program authorized in 21st Century Cures Act, and preventive medicine residency programs; report language regarding national standards for treatment programs Supported HR 3496 & S 1983 CREATE Opportunities Act - grants to, and cooperative agreements with, state and local governments to develop, implement, or expand medication-assisted treatment for incarcerated individuals who are addicted to opioids. Supported HR 2569 & S 1365 - Comprehensive Addiction Resources Emergency Act - to provide emergency assistance to States, territories, Tribal nations, and local areas affected by the opioid epidemic and to make financial assistance available to States, territories, Tribal nations, local areas, and public or private nonprofit entities to provide for the development, organization, coordination, and operation of more effective and cost efficient systems for the delivery of essential services to individuals with substance use disorder and their families. Advocated for additional evidence-based standards. Supported HR 3414 (and prior versions)/ S. 2892 - Opioid Workforce Act of 2019 - bill increases the number of residency positions eligible for graduate medical education payments under Medicare for hospitals that have addiction or pain management programs, with an aggregate increase of 1,000 positions over a five-year period. Supported HR 3165 and S 1737 - Mental Health Parity Compliance Act - strengthen parity in mental health and substance use disorder benefits. Advocated for its inclusion in the Lower Health Care Costs Act of 2019. Supported S 873 and HR 1879 - Stabilize Medicaid and CHIP Coverage Act which would provide for 12 months of continuous enrollment in Medicaid and CHIP to ensure better access to care and reduce churn. This bill is not specific to mental health, but it would provide significant stability to those patients and providers. Supported H.R.2062/S. 1012 - To amend the Public Health Service Act to protect the confidentiality of substance use disorder patient records. Supported H.R.1920 - Medicaid Bump Act - To amend title XIX of the Social Security Act to provide a higher Federal matching rate for increased expenditures under Medicaid for mental and behavioral health services, and for other purposes. Supported H.R.1329 - Medicaid Reentry Act - This bill allows Medicaid payment for medical services furnished to an incarcerated individual during the 30-day period preceding the individual's release. Supported S 824/HR 1767 - Excellence in Mental Health and Addiction Treatment Expansion Act This legislation would extend and expand the Certified Community Behavioral Health Clinic (CCBHC) demonstration, which is set to end in mid-2019. Supported the Parity Enforcement Act (HR 2848). This legislation would give the U.S. Department of Labor authority to levy civil monetary penalties against health insurers and plan sponsors for parity violations of the Paul Wellstone and Pete Domenici Mental Health Parity and Addiction Equity Act of 2008. Supported HR 2734/S 1448 - Safer Prescribing of Controlled Substances Act. The bill calls for mandatory education for practitioners licensed to dispense or conduct research with controlled substances in schedule II, III, IV, or V. The education, which would be required as part of a prescribers DEA licensure registration and renewal, will focus on best practices for pain management and alternative non-opioid therapies for pain, methods for diagnosing and treating a substance use disorder, linking patients to evidence-based treatment for substance use disorder, and tools to manage adherence and diversion of controlled substances, including Prescription Drug Monitoring Programs. Supported S.1012/ HR 2062 Protecting Jessica Grubbs Legacy Act/ Overdose Prevention and Patient Safety Act to amend the Public Health Service Act to protect the confidentiality of substance use disorder patient records. Supported HR 4974: the MATE Act - to amend the Controlled Substances Act to require physicians and other prescribers of controlled substances to complete training on treating and managing patients with opioid and other substance use disorders (which shall also satisfy certain training required to receive a waiver for dispensing narcotic drugs for maintenance or detoxification treatment),and for other purposes. Advocated for reduction of barriers to buprenorphine related to treatment of hospitalized patients. Supported the Marijuana and Cannabidiol Research Expansion Act. This legislation would enable the expansion of the scientific research base on marijuana to answer critical questions, such as identifying potential therapeutic effects and possible public health consequences. Supported the Medical Marijuana Research Act of 2019, which would reduce many of the burdensome barriers researchers face when conducting legitimate scientific research involving cannabis. The bill would ensure that a supply of cannabis is continuously available to researchers, streamline various cannabis related application processes that run through the Department of Justice, and require the Department of Health and Human Services to conduct a review of existing research on cannabis. Supported a conditional endorsement of The Mainstreaming Addiction Treatment Act, which is contingent upon the elimination of DEA regulations on medications in Schedules III-V that are based on the prescribing intent to treat addiction and a requirement that all DEA controlled substance prescribers complete medical education on addiction. Supported the Humane Correctional Health Care Act , H.R. 4141/S. 2305, which would repeal the Medicaid Inmate Exclusion. The exclusion strips health coverage from Medicaid enrollees who are involved in the criminal justice system. Supported H.R. 3925, the Reducing Barriers to Substance Use Treatment Act, introduced by Representatives Paul Tonko (D-NY) and David McKinley (R-VA). The bill would prohibit state Medicaid programs, beginning in October 1, 2020, and ending September 30, 2025, from imposing prior authorizations or other types of utilization control policies or procedures on medications approved to treat OUD, including, with respect to the provision of those medications, counseling services and behavioral therapy. Support the Stopping Appealing Flavors in E-Cigarettes for Kids Act (SAFE Kids Act), introduced by Senator Dick Durbin and Senator Lisa Murkowski (S. 655) and Representative Diana DeGette and Representative Jamie Raskin (H.R. 1498). The bill would prohibit flavors in e-cigarettes unless the manufacturer demonstrates that a flavor will help with smoking cessation, not increase youth initiation, and not increase the risk of harm to the user. It furthermore prohibits use of flavors in other non-cigarette tobacco products, such as cigars and smokeless tobacco. Opposed the Traditional Cigar Manufacturing and Small Business Jobs Preservation Act of 2019, which would prohibit FDA from promulgating any public health protections related to what the cigar industry calls traditional large and premium cigars. Even the most basic Food and Drug Administration (FDA) requirements like ingredient disclosure and warning labels as well as enforcement of youth access laws would not apply to these products. Supported the Reversing the Youth Tobacco Epidemic Act of 2019 (HR 2339) which would, among other things, amend the Federal Food, Drug, and Cosmetic Act with respect to the sale and marketing of tobacco products Submitted comments on amendments to regulations under the Federal anti-kickback statute (AKS). The proposed amendments would modify and add new safe harbors under the statute and exceptions to the beneficiary inducements civil monetary penalty definition of remuneration to foster arrangements that would promote care coordination and advance the delivery of value-based care while also protecting patients and taxpayer dollars against harms caused by fraud and abuse. Supported H.Res. 714: Recognizing addiction as a disease and supporting efforts to prevent, treat, and destigmatize substance use disorder and addiction. Submitted a response to a request for information (RFI) regarding substance use disorder (SUD) treatment by Representatives Greg Walden, Michael Burgess, and Brett Guthrie, Republican leaders of the House Committee on Energy and Commerce. The RFI focused on challenges, failures, fraud and abuse within the SUD treatment industry, as well as opportunities to improve the quality of treatment. Provided comments to ONDCP regarding next National Drug Control Strategy per invitation, focusing on addiction treatment workforce, setting standards, monitoring program effectiveness, coverage for addiction treatment services.

Client expense: $70,000 · Firm income: Not reported

Government targets: Drug Enforcement Administration (DEA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Office of Natl Drug Control Policy (NDCP), SENATE

Advocated for FY2020 Labor HHS Appropriations bill - appropriations related to strengthening the addiction services workforce, including full funding of the loan repayment program for the substance use disorder treatment workforce authorized in the SUPPORT Act, the mental and substance use disorders training demonstration program authorized in 21st Century Cures Act, and preventive medicine residency programs; report language regarding national standards for treatment programs Supported HR 3496 & S 1983 CREATE Opportunities Act - grants to, and cooperative agreements with, state and local governments to develop, implement, or expand medication-assisted treatment for incarcerated individuals who are addicted to opioids. Supported HR 2569 & S 1365 - Comprehensive Addiction Resources Emergency Act - to provide emergency assistance to States, territories, Tribal nations, and local areas affected by the opioid epidemic and to make financial assistance available to States, territories, Tribal nations, local areas, and public or private nonprofit entities to provide for the development, organization, coordination, and operation of more effective and cost efficient systems for the delivery of essential services to individuals with substance use disorder and their families. Advocated for additional evidence-based standards. Supported HR 3414 (and prior versions)/ S. 2892 - Opioid Workforce Act of 2019 - bill increases the number of residency positions eligible for graduate medical education payments under Medicare for hospitals that have addiction or pain management programs, with an aggregate increase of 1,000 positions over a five-year period. Supported HR 3165 and S 1737 - Mental Health Parity Compliance Act - strengthen parity in mental health and substance use disorder benefits. Advocated for its inclusion in the Lower Health Care Costs Act of 2019. Supported S 873 and HR 1879 - Stabilize Medicaid and CHIP Coverage Act which would provide for 12 months of continuous enrollment in Medicaid and CHIP to ensure better access to care and reduce churn. This bill is not specific to mental health, but it would provide significant stability to those patients and providers. Supported H.R.2062/S. 1012 - To amend the Public Health Service Act to protect the confidentiality of substance use disorder patient records. Supported H.R.1920 - Medicaid Bump Act - To amend title XIX of the Social Security Act to provide a higher Federal matching rate for increased expenditures under Medicaid for mental and behavioral health services, and for other purposes. Supported H.R.1329 - Medicaid Reentry Act - This bill allows Medicaid payment for medical services furnished to an incarcerated individual during the 30-day period preceding the individual's release. Supported S 824/HR 1767 - Excellence in Mental Health and Addiction Treatment Expansion Act This legislation would extend and expand the Certified Community Behavioral Health Clinic (CCBHC) demonstration, which is set to end in mid-2019. Supported the Parity Enforcement Act (HR 2848). This legislation would give the U.S. Department of Labor authority to levy civil monetary penalties against health insurers and plan sponsors for parity violations of the Paul Wellstone and Pete Domenici Mental Health Parity and Addiction Equity Act of 2008. Supported HR 2734/S 1448 - Safer Prescribing of Controlled Substances Act. The bill calls for mandatory education for practitioners licensed to dispense or conduct research with controlled substances in schedule II, III, IV, or V. The education, which would be required as part of a prescribers DEA licensure registration and renewal, will focus on best practices for pain management and alternative non-opioid therapies for pain, methods for diagnosing and treating a substance use disorder, linking patients to evidence-based treatment for substance use disorder, and tools to manage adherence and diversion of controlled substances, including Prescription Drug Monitoring Programs. Supported S.1012/ HR 2062 Protecting Jessica Grubbs Legacy Act/ Overdose Prevention and Patient Safety Act to amend the Public Health Service Act to protect the confidentiality of substance use disorder patient records. Supported HR 4974: the MATE Act - to amend the Controlled Substances Act to require physicians and other prescribers of controlled substances to complete training on treating and managing patients with opioid and other substance use disorders (which shall also satisfy certain training required to receive a waiver for dispensing narcotic drugs for maintenance or detoxification treatment),and for other purposes. Supported the Marijuana and Cannabidiol Research Expansion Act. This legislation would enable the expansion of the scientific research base on marijuana to answer critical questions, such as identifying potential therapeutic effects and possible public health consequences. Supported the Medical Marijuana Research Act of 2019, which would reduce many of the burdensome barriers researchers face when conducting legitimate scientific research involving cannabis. The bill would ensure that a supply of cannabis is continuously available to researchers, streamline various cannabis related application processes that run through the Department of Justice, and require the Department of Health and Human Services to conduct a review of existing research on cannabis. Supported a conditional endorsement of The Mainstreaming Addiction Treatment Act, which is contingent upon the elimination of DEA regulations on medications in Schedules III-V that are based on the prescribing intent to treat addiction and a requirement that all DEA controlled substance prescribers complete medical education on addiction. Supported the Humane Correctional Health Care Act , H.R. 4141/S. 2305, which would repeal the Medicaid Inmate Exclusion. The exclusion strips health coverage from Medicaid enrollees who are involved in the criminal justice system. Supported H.R. 3925, the Reducing Barriers to Substance Use Treatment Act, introduced by Representatives Paul Tonko (D-NY) and David McKinley (R-VA). The bill would prohibit state Medicaid programs, beginning in October 1, 2020, and ending September 30, 2025, from imposing prior authorizations or other types of utilization control policies or procedures on medications approved to treat OUD, including, with respect to the provision of those medications, counseling services and behavioral therapy. Support the Stopping Appealing Flavors in E-Cigarettes for Kids Act (SAFE Kids Act), introduced by Senator Dick Durbin and Senator Lisa Murkowski (S. 655) and Representative Diana DeGette and Representative Jamie Raskin (H.R. 1498). The bill would prohibit flavors in e-cigarettes unless the manufacturer demonstrates that a flavor will help with smoking cessation, not increase youth initiation, and not increase the risk of harm to the user. It furthermore prohibits use of flavors in other non-cigarette tobacco products, such as cigars and smokeless tobacco. Opposed the Traditional Cigar Manufacturing and Small Business Jobs Preservation Act of 2019, which would prohibit FDA from promulgating any public health protections related to what the cigar industry calls traditional large and premium cigars. Even the most basic Food and Drug Administration (FDA) requirements like ingredient disclosure and warning labels as well as enforcement of youth access laws would not apply to these products. Supported the Reversing the Youth Tobacco Epidemic Act of 2019 (HR 2339) which would, among other things, amend the Federal Food, Drug, and Cosmetic Act with respect to the sale and marketing of tobacco products Submitted comments on amendments to regulations under the Federal anti-kickback statute (AKS). The proposed amendments would modify and add new safe harbors under the statute and exceptions to the beneficiary inducements civil monetary penalty definition of remuneration to foster arrangements that would promote care coordination and advance the delivery of value-based care while also protecting patients and taxpayer dollars against harms caused by fraud and abuse. Supported H.Res. 714: Recognizing addiction as a disease and supporting efforts to prevent, treat, and destigmatize substance use disorder and addiction. Submitted a response to a request for information (RFI) regarding substance use disorder (SUD) treatment by Representatives Greg Walden, Michael Burgess, and Brett Guthrie, Republican leaders of the House Committee on Energy and Commerce. The RFI focused on challenges, failures, fraud and abuse within the SUD treatment industry, as well as opportunities to improve the quality of treatment. Provided comments to ONDCP regarding next National Drug Control Strategy per invitation, focusing on addiction treatment workforce, setting standards, monitoring program effectiveness, coverage for addiction treatment services.

Client expense: $70,000 · Firm income: Not reported

Government targets: Drug Enforcement Administration (DEA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Office of Natl Drug Control Policy (NDCP), SENATE

Prescription Drugs S. 340, H.R. 965 - Creating and Restoring Equal Access to Equivalent Samples Act of 2019 CREATES Act of 2019" - promote competition in the market for drugs and biological products by facilitating the timely entry of entry of lower-cost generic and biosimilar versions of those drugs and biological products. H.R. 3 - The Lower Drug Costs Now Act S. 99, H.R. 448 - Medicare Drug Price Negotiation Act Average Wholesale Price of Pharmaceuticals in Ads - no specific bill H.R. 2113 Prescription Drug STAR Act - Transparency of pharmaceutical prices across all sectors Safety of imported drug components - no specific bill Surprise Billing H.R. 3502 - Protecting People from Surprise Medical Bills Act S. 1895 - Lower Health Care Costs Act H.R. 3630 - No More Surprises Act H.R. 3502 - Protecting People From Surprise Medical Bills Act S. 967 - Resolving Unanticipated Bills Act Gun Violence H.R. 8, S. 42 Background Checks of 2019 - Legislation to close loopholes in background checks for guns S. 184, H.R. 674 Gun Violence Prevention Research Act - Legislation to authorize CDC funds into prevention gun violence research LABOR-HHS Appropriations to fund gun violence research Comprehensive gun control legislation Medicare/Medicaid S. 1129 - A bill to establish a Medicare-for-all national health insurance program H.R.1384 - Medicare for All Act of 2019 S. 470 - Medicare at 50 Act H.R. 1346 - Medicare Buy-In and Health Care Stabilization Act of 2019 H.R. 1419 - Public Option Deficit Reduction Act S. 981, H.R. 2000 - Medicare-X Choice Act of 2019 S. 296, H.R. 2150 - Home Health Care Planning Improvement Act of 2019 ACA Protections Changes to MACRA - no specific bill Social Determinants of Health Increased federal funds for community-based food programs which provide medically tailored meals to poor, sick, immobile patients and their families - no specific bill Opioids and Substance Use Disorder H.R. 2734 - Safer Prescribing of Controlled Substances Act - Federal Prescriber Education Mandates S. 1365, H.R. 2569 - Comprehensive Addiction Resources Emergency Act of 2019 Maternal Mortality H.R. 2602 - Healthy MOMMIES Act - extending Medicare ACA coverage and access to maternity care Recommendations to address racial disparities and social determinants in the national maternal mortality crisis Prior Authorization H.R. 3170 - Improving Seniors Timely Access to Care Act of 2019 Publications Open access to information based on publicly funded research Regulations Executive Order entitled, "Protecting and Improving Medicare for our Nation's Seniors." CMS- Proposed changes to Medicaid Funding

Client expense: $80,000 · Firm income: Not reported

Government targets: Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE

Prescription Drugs S. 340, H.R. 965 - Creating and Restoring Equal Access to Equivalent Samples Act of 2019 CREATES Act of 2019" - promote competition in the market for drugs and biological products by facilitating the timely entry of entry of lower-cost generic and biosimilar versions of those drugs and biological products. H.R. 3 - The Lower Drug Costs Now Act S. 99, H.R. 448 - Medicare Drug Price Negotiation Act Average Wholesale Price of Pharmaceuticals in Ads - no specific bill H.R. 2113 Prescription Drug STAR Act - Transparency of pharmaceutical prices across all sectors Safety of imported drug components - no specific bill Surprise Billing H.R. 3502 - Protecting People from Surprise Medical Bills Act S. 1895 - Lower Health Care Costs Act H.R. 3630 - No More Surprises Act H.R. 3502 - Protecting People From Surprise Medical Bills Act S. 967 - Resolving Unanticipated Bills Act Gun Violence H.R. 8, S. 42 Background Checks of 2019 - Legislation to close loopholes in background checks for guns S. 184, H.R. 674 Gun Violence Prevention Research Act - Legislation to authorize CDC funds into prevention gun violence research LABOR-HHS Appropriations to fund gun violence research Comprehensive gun control legislation Medicare/Medicaid S. 1129 - A bill to establish a Medicare-for-all national health insurance program H.R.1384 - Medicare for All Act of 2019 S. 470 - Medicare at 50 Act H.R. 1346 - Medicare Buy-In and Health Care Stabilization Act of 2019 H.R. 1419 - Public Option Deficit Reduction Act S. 981, H.R. 2000 - Medicare-X Choice Act of 2019 S. 296, H.R. 2150 - Home Health Care Planning Improvement Act of 2019 ACA Protections Changes to MACRA - no specific bill Social Determinants of Health Increased federal funds for community-based food programs which provide medically tailored meals to poor, sick, immobile patients and their families - no specific bill Opioids and Substance Use Disorder H.R. 2734 - Safer Prescribing of Controlled Substances Act - Federal Prescriber Education Mandates S. 1365, H.R. 2569 - Comprehensive Addiction Resources Emergency Act of 2019 Maternal Mortality H.R. 2602 - Healthy MOMMIES Act - extending Medicare ACA coverage and access to maternity care Recommendations to address racial disparities and social determinants in the national maternal mortality crisis Prior Authorization H.R. 3170 - Improving Seniors Timely Access to Care Act of 2019 Publications Open access to information based on publicly funded research Regulations Executive Order entitled, "Protecting and Improving Medicare for our Nation's Seniors." CMS- Proposed changes to Medicaid Funding

Client expense: $80,000 · Firm income: Not reported

Government targets: Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE

Opioids and Substance Use Disorder H.R. 2734 - Safer Prescribing of Controlled Substances Act - Federal Prescriber Education Mandates S. 1365, H.R. 2569 - Comprehensive Addiction Resources Emergency Act of 2019

Client expense: $80,000 · Firm income: Not reported

Government targets: Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE

Support H.R. 2569, the Comprehensive Addiction Resources Emergency (CARE) Act of 2019.

Client expense: $19,878 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE

H.R. 3591: Campus Prevention and Recovery Services for Students Act of 2019 H.R. 2466: State Opioid Response Grant Authorization Act H.R. 2922: Respond Now Act H.R. 3489, S. 1204: Higher Education Mental Health Act of 2019 H.R. 3496, S. 1983: Create Opportunities Act H.R. 2569, S. 1365: Comprehensive Addiction Resources Emergency Act

Client expense: $200,000 · Firm income: Not reported

Government targets: Agency for Healthcare Research & Quality (AHRQ), Agriculture, Dept of (USDA), Centers For Disease Control & Prevention (CDC), Commerce, Dept of (DOC), Defense, Dept of (DOD), Education, Dept of, Employment & Training Administration, Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), Justice, Dept of (DOJ), Labor, Dept of (DOL), Natl Institutes of Health (NIH), Natl Science Foundation (NSF), Natl Security Agency (NSA), SENATE, Substance Abuse & Mental Health Services Administration (SAMHSA), Veterans Affairs, Dept of (VA)

H.Res. 419, Resolution recognizing the contributions of the Addiction Profession workforce The Comprehensive Addiction Resources Emergency (CARE) Act (S. 1365, H.R. 2569) H.R. 2767, Supporting Eating Disorders Recovery through Vital Expansion (SERVE) Act The Parity Enforcement Act (HR 2848) The Behavioral Health Coverage Transparency Act (HR.2874, S.1576) Mental Health Parity Compliance Act (H.R.3165, S.1737) Protecting Pre-Existing Conditions and Making Health Care Affordable Act of 2019 (H.R. 1884) The Medicaid Reentry Act (H.R. 1329) S. 2412, the Addiction Treatment Access Act SUD privacy standards (42 CFR Part 2) H.R. 2062, The Overdose Prevention and Patient Safety Act Surprise Medical Billing compromise - timely billing and SUD parity S.2974 - USPS Opioid & Illicit Drug Strategy Act of 2019

Client expense: Not reported · Firm income: $20,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

H.R.1309 - Workplace Violence Prevention for Health Care and Social Service Workers Act H.R. 3630 No Surprises Act (Provisions protecting consumers from surprise medical bills and setting payment rates for providers) HR 1603/ S. 717--Alan Reinstein Ban Asbestos Now Act of 2019 H.R. 3 Lower Drug Costs Now Act of 2019 (Provisions related to drug price negotiation, inflation rebates, Medicare Part D benefit restructuring) H.R. 2569 - Comprehensive Addiction Resources Emergency Act -Oversight strategy on job safety and health issues HR 3502 - Protecting People from Surprise Medical Bills Act S. 1895 - Lower Health Care Costs Act

Client expense: $760,000 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, SENATE, U.S. Trade Representative (USTR)

H.R.1763 / S. 348, the Resident Physician Shortage Reduction Act of 2019 H.R. 2062 / S. 1012 (42 CFR Part 2) H.R. 1585, the Violence Against Women Reauthorization Act H.R. 5, the Equality Act H.R. 1109, the Mental Health Services for Students Act of 2019 S. 824, the Excellence in Mental Health and Addiction Treatment Expansion Act H.R. 2300 Eliminating Debtor's Prison for Kids Act of 2019 Activity to promote evidence-based trauma-informed care Out of network billing legislation H.R. 2569/S. 1365, the CARE Act H.R. 3414, the Opioid Workforce Act S. 1895, the Lower Health Care Costs Act H.R. 3496, the CREATE Opportunities Act S. 1227, the Prescription Pricing for the People Act of 2019 H.R. 2874 / S. 1576, the Behavioral Health Coverage Transparency Act S.1659, the Ensuring Childrens Access to Specialty Care Act of 2019 H.R. 3253, the Empowering Beneficiaries, Ensuring Access, and Strengthening Accountability Act H.R. 1554, the Resident Education Deferred Interest Act H.R. 3239, the Humanitarian Standards for Individuals in Customs and Border Protection Custody Act H.R. 3180/ S. 1770, the RISE from Trauma Act H.R. 2862, the VACCINES Act of 2019 H.R. 4309, the Barriers to Suicide Act H.R. 2569/S. 1365, the Comprehensive Addiction Resources Emergency (CARE) Act H.R. 2279, the Safe Step Act H.R. 4327, the Enhancing Mental Health and Suicide Prevention Through Campus Planning Act H.R. 3735, the Law Enforcement Suicide Data Collection Act H.R. 3417, BETTER Act of 2019 H. Res. 337, Expressing support for the designation of May 2019 as "Mental Health Awareness Month H. Res. 587, Recognizing LGBTQ+ suicide as a public health problem and expressing support for the designation of September as "National Suicide Prevention Month" H. Res. 480, Acknowledging the racial disparities in diagnosing and treating mental health among youth in communities of color S. 1227, the Prescription Pricing for the People Act of 2019 H.R. 3, Lower Drug Costs Now Act of 2019 H.R. 2734 / S. 1448, the Safer Prescribing of Controlled Substances Act H.R. 2482/ S. 2074, the Mainstreaming Addiction Treatment Act of 2019 Title X Family Planning Program Administration Rule Maternal mortality legislation

Client expense: $236,000 · Firm income: Not reported

Government targets: Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Defense, Dept of (DOD), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Institutes of Health (NIH), SENATE, Veterans Affairs, Dept of (VA), White House Office

H.R. 447: Affordable and Safe Prescription Drug Importation Act - Provisions related to importation H.R. 478: Safe and Affordable Drugs from Canada Act of 2019 - Provisions related to importation H.R. 965: Creating and Restoring Equal Access to Equivalent Samples (CREATES) Act of 2019 - Provisions related to Risk Evaluation and Mitigation Strategies (REMS) and limited distribution systems H.R. 985: FAST Generics Act of 2019 - Provisions related to Risk Evaluation and Mitigation Strategies (REMS) and limited distribution systems H.R. 1093: Stop Price Gouging Act - Provisions related to prescription drug pricing H.R. 1332: Fair Care Act of 2019 - Provisions related to prescription drug pricing, patent issues, Risk Evaluation and Mitigation Strategies (REMS) and limited distribution systems H.R. 1409: Transparency in All Health Care Pricing Act of 2019 - Provisions related to prescription drug pricing transparency H.R. 1478: Affordable Insulin Act of 2019 - Provisions related to importation H.R. 1506: Fair and Immediate Release (FAIR) of Generic Drugs Act - Provisions related to generic prescription drug approvals H.R. 1603: Alan Reinstein Ban Asbestos Now Act of 2019 - Provisions related to use of asbestos in manufacturing H.R. 2038: State-Based, Market-Oriented, Prescription Drug Negotiations Act of 2019 - Provisions related to prescription drug pricing H.R. 2064: To amend title XI of the Social Security Act to require manufacturers of certain drugs, devices, biologicals, and medical supplies to report on product samples provided to certain health care providers, and for other purposes - Provisions related to prescription drug samples H.R. 2069: Stopping the Pharmaceutical Industry from Keeping Drugs Expensive (SPIKE) Act of 2019 - Provisions related to increases in the wholesale acquisition costs of prescription drugs H.R. 2087: Drug Price Transparency Act - Provisions related to prescription drug pricing and transparency H.R. 2113: Prescription Drug STAR Act - Provisions related to prescription drug pricing, reporting and product samples H.R. 2115: Public Disclosure of Drug Discounts Act - Provisions related to prescription drug pricing transparency and pharmacy benefit managers H.R. 2296: FAIR Drug Pricing Act of 2019 / More Efficient Tools to Realize Information for Consumers Act - Provisions related to prescription drug pricing and transparency H.R. 2376: Prescription Pricing for the People Act of 2019 - Provisions related to prescription drug pricing transparency and pharmacy benefit managers H.R. 2401: American Cures Act - Provisions related to pharmaceutical research and development H.R. 2569: Comprehensive Addiction Resources Emergency Act of 2019 - Provisions related to opioid crisis response funding H.R. 2734: Safer Prescribing of Controlled Substances Act - Provisions related to the prescribing of prescription drugs H.R. 2917: Opioid Crisis Accountability Act of 2019 - Provisions related to prescription drug marketing H.R. 3223: Pharmacy Benefit Manager Accountability Study Act of 2019 - Provisions related to prescription drug pricing transparency and pharmacy benefit managers H.R. 3327: Drug Price Transparency for Medicare Patients Act of 2019 - Provisions related to direct-to-consumer prescription drug advertising H.R. 3415: Real-Time Beneficiary Drug Cost Bill - Provisions related to drug pricing transparency H.R. 3443: Over-the-Counter Monograph Safety, Innovation, and Reform Act of 2019 - Provisions related to FDA over-the-counter drug approvals H.R. 3947: Competition Prescription Act of 2019 - Provisions related to prescription drug pricing, patents, and other provisions H.R. 4106: Responsibility in Drug Advertising Act of 2019 - Provisions related to direct-to-consumer prescription drug advertising H.R. 4158: CURE High Drug Prices Act - Provisions related to prescription drug pricing and transparency H.R. 4538: To amend title III of the Public Health Service Act to limit the orphan drug exclusion under the drug discount program under section 340B of such title. - Provisions related to 340B prescription drug exclusions S. 61: Safe and Affordable Drugs from Canada Act of 2019 - Provisions related to importation S. 73: End Taxpayer Subsidies for Drug Ads Act - Provisions related to direct-to-consumer prescription drug advertising S. 97: Affordable and Safe Prescription Drug Importation Act - Provisions related to importation S. 340: Creating and Restoring Equal Access to Equivalent Samples (CREATES) Act of 2019 - Provisions related to Risk Evaluation and Mitigation Strategies (REMS) and limited distribution systems S. 378: Stop Price Gouging Act - Provisions related to prescription drug pricing S. 440: PACED Act - Provisions related to use of sovereign immunity in patent disputes S. 474: Stopping the Pharmaceutical Industry from Keeping Drugs Expensive (SPIKE) Act of 2019 - Provisions related to increases in the wholesale acquisition costs of prescription drugs S. 637: Combatting Unreasonable Rises and Excessively (CURE) High Drug Prices Act - Provisions related to prescription drug pricing and transparency S. 657: Drug Price Transparency Act - Provisions related to prescription drug pricing transparency and commercial market rebates S. 660: Efficiency and Transparency in Petitions Act - Provisions related to the FDA citizen petition process S. 844: Short on Competition Act - Provisions related to generic prescription drug approvals and importation S. 977: Transparent Drug Pricing Act of 2019 - Provisions related to pharmaceutical drug pricing S. 1140: Protecting Access to Biosimilars Act of 2019 - Provisions related to biological products S. 1227: Prescription Pricing for the People Act of 2019 - Provisions related to prescription drug pricing transparency and pharmacy benefit managers S. 1384: Prescription Drug Rebate Reform Act of 2019 - Provisions related to prescription drug pricing and commercial rebates S. 1391: FAIR Drug Pricing Act of 2019 - Provisions related to prescription drug pricing and transparency S. 1437: Drug-price Transparency in Communications (DTC) Act - Provisions related to direct-to-consumer prescription drug advertising S. 1532: Pharmacy Benefit Manager Accountability Study Act of 2019 - Provisions related to prescription drug pricing transparency and pharmacy benefit managers S. 1664: Prescription Drug Price Reporting Act - Provisions related to prescription drug pricing transparency S. 2103: Affordable Insulin Approvals Now Act - Provisions related to FDA prescription drug approvals S. 2161: Reciprocity Ensures Streamlined Use of Lifesaving Treatments Act of 2019 - Provisions related to reciprocity S. 2199: Insulin Price Reduction Act - Provisions related to prescription drug pricing and transparency S. 2387: We Protect American Investment in Drugs Act - Provisions related to prescription drug pricing Transparency policy issues Drug cost and pricing policy issues Drug importation and counterfeiting policy issues HHS Safe Importation Action Plan Prescription drug take back and secure disposal policy issues Policy issues related to prescription drug abuse and opioids Expanded access policy issues Generic drug approval process policy issues High deductible health plans/HSA policy issues Sharing of truthful and non-misleading information about medicines with healthcare professionals and payors Risk Evaluation and Mitigation Strategy (REMS) policy issues FDA modernization policy issues PDUFA implementation policy issues 340B drug discount program policy issues Bipartisan Budget Act of 2018 (Public Law 115-123) - Part D provisions Patient assistance program policy issues Biosimilar approval and reimbursement policy issues Cancer drug vial size policy issues TRICARE pharmacy pilot program Drug shortages policy issues Request for Information: HHS Blueprint to Lower Drug Prices and Reduce Out-of-Pocket Costs (RIN 0991-ZA49)

Client expense: $6,230,000 · Firm income: Not reported

Government targets: Centers For Medicare and Medicaid Services (CMS), Executive Office of the President (EOP), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Economic Council (NEC), Office of Management & Budget (OMB), Patent & Trademark Office (PTO), President of the U.S., SENATE, U.S. Trade Representative (USTR)

Maternal and child health legislation,focusing on National Children's Study (ECHO), Zika preparedness, tobacco control, opioids legislation and neonatal abstinence syndrome (NAS), antibiotic resistance, environmental health, vaccination, newborn screening, Healthy Start, maternal mental health. Specific legislation includes: MOMMAs Act (H.R. 1897/S. 916, MOMs Act (S. 116),MOMMIES Act (H.R. 2602, S. 1343), Quality Care for Moms and Babies Act (H.R. 1551/S. 1960), Maternal CARE Act (H.R. 6698/S. 1600), The Healthy Maternity and Obstetric Medicine Act (Healthy MOM Act) (H.R. 2778/S. 1481), Rural Maternal and Obstetric Modernization of Services (MOMS) Act (S. 2373), and the Maternal Outcomes Matter Act of 2019 (S. 2586), (H.R. 2778, S. 1481),Reversing the Youth Tobacco Epidemic Act (H.R. 2339), Public Health Funding Restoration Act (H.R. 3447, S. 1944), and the Comprehensive Addiction Resources Emergency CARE Act (H.R. 2569, S. 1365), Newborn Screening Saves Lives Reauthorization Act of 2019 (HR 2507/S. 2158), Traveling Parents Screening Consistency Act (HR 3246), and the Tobacco Tax Equity Act (S. 2517).

Client expense: $30,000 · Firm income: Not reported

Government targets: Agriculture, Dept of (USDA), Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Environmental Protection Agency (EPA), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), Internal Revenue Service (IRS), Labor, Dept of (DOL), Natl Institutes of Health (NIH), Postal Regulatory Commission, SENATE, Treasury, Dept of, U.S. Postal Service (USPS)

Teaching Health Centers; Health Information Technology and TeleHealth; Substance abuse and opioid use; 340B Drug Discount Program; Title X Program, Training the Next Generation of Primary Care Doctors(S.304/H.R.2815); Funding for School-Based Health Centers(S.1365/H.R.2569); Lower Drug Costs Now Act of 2019 (H.R. 3).

Client expense: $230,000 · Firm income: Not reported

Government targets: Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, Health Resources & Services Administration (HRSA), Office of Management & Budget (OMB), SENATE, White House Office